



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : C07K 7/06, 7/08, 7/10 C12Q 1/70, G01N 33/53, 33/532	A1	(11) International Publication Number: WO 88/08005 (43) International Publication Date: 20 October 1988 (20.10.88)
(21) International Application Number: PCT/US88/01140 (22) International Filing Date: 8 April 1988 (08.04.88) (31) Priority Application Numbers: 8701628-3 083,682 (32) Priority Dates: 16 April 1987 (16.04.87) 7 August 1987 (07.08.87) (33) Priority Countries: SE US (71) Applicant: JOHNSON AND JOHNSON [US/US]; One Johnson and Johnson Plaza, New Brunswick, NJ 08933-7003 (US). (72) Inventors: NORRBY, Erling, C., J. ; Tykovagen 21, S- 181 61 Lidingo (SE). PARKS, D., Elliot ; 709 Kala- math Drive, Del Mar, CA 92014 (US). LERNER, Ri- chard, A. ; 7750 E. Roseland, La Jolla, CA 92037 (US).		(74) Agents: GAMSON, Edward, P.; Dressler, Goldsmith, Shore, Sutker & Milnamow, Ltd., 1800 Prudential Plaza, Chicago, IL 60601 (US) et al. (81) Designated States: AT (European patent), AU, BE (Eu- ropean patent), CH (European patent), DE (Euro- pean patent), DK, FI, FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). Published <i>With international search report.</i>
(54) Title: STLV-III-RELATED POLYPEPTIDES, DIAGNOSTIC SYSTEMS AND ASSAY METHODS (57) Abstract STLV-III-related polypeptides capable of immunological mimicking a specific linear antigenic determinant of the HIV-2 virus TMP protein are disclosed. Methods for using the disclosed STLV-III-related polypeptides to assay for the presence and amount of anti-HIV-2 antibodies in a body fluid sample are also disclosed. Further disclosed are diagnostic systems useful for detecting anti-HIV-2 antibodies and distinguishing between exposure to HIV-2 and HIV-1.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

STLV-III-RELATED POLYPEPTIDES, DIAGNOSTIC
SYSTEMS AND ASSAY METHODS

Description

5 Technical Field

The present invention contemplates a novel polypeptide antigen related to the simian virus STLV-III and to its use in diagnostic systems and assay methods.

10 Background of the Invention

The acquired immune deficiency syndrome (AIDS) has now spread worldwide and appears to be an acute public health problem, particularly in Africa. A retrovirus designated human immunodeficiency virus
15 type 1 (HIV-1), but previously known as LAV, HTLV-III or ARV, was shown to cause AIDS in the different areas afflicted by the epidemics, including North America, Western Europe and Central Africa.

Studies of HIV-1 at the molecular level have
20 revealed some differences in the nucleotide sequence of North-American and African isolates. This sequence variation is also present, though to a lesser extent, among different isolates from the USA. However, the North American, Western European and Central African
25 isolates appear to have similar biological properties and antigenically cross-reactive proteins with the same relative molecular mass.

Individuals infected with HIV-1 develop antibodies to the gag-gene encoded viral core proteins
30 designated p19, p24, and to their precursor protein designated p55. In addition, antibodies against env-gene encoded envelope glycoproteins gp120 (the extracellular glycoprotein or EGP), gp41 (the transmembrane protein or TMP) and their precursor
35 glycoprotein designated gp160 are also observed.

-2-

A large number of AIDS patients show a disappearance of antibodies to the HIV-1 core proteins at an advanced state of the disease, but retain antibodies immunoreactive with the envelope antigens. The envelope products are regularly detected by antibodies in sera from patients at different stages of HIV-1 infection. Although few reports are available on seroconversion to HIV-1, the emergence of antibodies to the envelope proteins seems to shortly precede emergence of antibodies to the core proteins. See Carlson et al., Lancet, i:361-362, (1987). For these reasons, the use of antigens representing the env-gene products have significant importance in diagnosis of exposure to AIDS related retroviruses.

Because AIDS can be transmitted by blood products, there has, from the initial recognition of the disease, been a strong impetus to develop diagnostic tests to screen blood for antibodies or antigens specific for the infecting virus. Efforts in this area have borne fruit, and by the end of 1985 five companies had been approved to market tests to detect antibodies to HIV-1 virus. These tests all rely for detection of those antibodies on the use of viral proteins obtained from cultured HIV-infected T-lymphocytes. The virus obtained from the cultured cells is disrupted (e.g., with detergent) and a fluid (called "viral lysate") is obtained. This lysate (containing a variety of fragments of viral and cellular protein) is then typically used as the solid phase component of an immunoassay.

While the existing tests appear to have significantly diminished the transmission of HIV-1 via blood products, the viral lysate based tests have some significant disadvantages, including results that indicate a high rate of false positives. The false

-3-

positives are thought to be due in part to the presence of non-viral proteins in the viral lysate preparations used in the solid phase component of the current assays.

5 In an attempt to reduce the rate of false positive results, the art has begun to develop site-directed serological assays employing synthetic polypeptides that mimic naturally occurring antigenic determinants on viral proteins. For instance, the
10 United States Patent No. 4,629,783 to Cosand, Wang et al., Proc. Natl. Acad. Sci. USA, 83:6159-6163 (1986), and Kennedy et al., Science, 231:1556-1559 (1986) describe several polypeptides said to be capable of mimicking antigenic determinants formed by various
15 HIV-1 proteins, including the TMP (gp41). United States Patent Applications No. 843,437, filed March 24, 1986, and No. 25,108, filed March 30, 1987, both assigned to Johnson & Johnson, Inc., New Brunswick, NJ, also describe HIV-1 TMP-related polypeptides.
20 Disclosures similar to those contained in the first application identified above were made by Rosen et al. at the Second International Conference on AIDS in Paris, France in June, 1986.

Another significant disadvantage of the
25 current methods for diagnosing exposure to AIDS-related viruses is that they rely on the use of HIV-1 derived antigens and thus give false negative results for individuals exposed to the antigenically distinct West African AIDS-related retroviruses, designated
30 herein as HIV type 2 (HIV-2). More than 20 HIV-2 isolates have been made from patients with AIDS and related conditions, mainly from West Africans, but also from some Europeans. Thus, an assay specific for HIV-2 is needed for screening donated blood and for

35

-4-

diagnosis of HIV-2 infection. Bruin-Vezinet, Lancet, i:128-132 (1987).

HIV-2 is structurally, biologically and antigenically related to HIV-1 and the simian T-lymphotrophic virus type III isolated from macaques (STLV-III_{mac}), a virus causing an AIDS-like disease in its simian host. All three viruses appear to contain EMP and TMP proteins that are formed by cleavage of a precursor protein. However, the apparent molecular weight of each of these proteins varies between HIV-1, HIV-2 and STLV-III and is thus one feature that can be used to distinguish among these viruses. For instance, the apparent molecular weight, in kilodaltons, of the TMPs of HIV-1, HIV-2 and STLV-III_{mac} are 41, 36, and 32, respectively.

Each of HIV-1, HIV-2 and STLV-III_{mac} also exhibit cytopathogenicity and tropism for cells carrying the CD4(T4) antigen (T4 lymphocytes). In addition, all three viruses have antigenically cross-reactive core proteins. Daniel et al., Science, 228:1201-04 (1985); Bruin-Vezinet et al., supra. However, while the envelope proteins, including the TMPs, of HIV-2 and STLV-III_{mac} are antigenically cross-reactive, neither appears to share antigenic determinants with the HIV-1 TMP. Clavel et al., Science, 233:343-346 (1986).

While the DNA sequence of the env-gene of STLV-III_{mac} has not been reported, Guyader et al., Nature, 326:662-669 (1987) have reported both the DNA sequence and the deduced amino acid residue sequence of the HIV-2 env-gene protein products. In comparing the EGP proteins of HIV-1 and HIV-2, Guyader et al. found them to be "very distantly related" because there was only 44.8% homology in their amino acid residue sequences. Similarly, the amino acid residue

-5-

sequences of the HIV-1 and HIV-2 TMP proteins were only 44.8% homologous. However, even to obtain these levels of homology, Guyader et al. had to put large insertions into the amino acid residue sequences, particularly when aligning the EGPs where only short, widely separated domains are conserved between HIV-1 and HIV-2.

Guyader et al. also reported that 22 of 23 cysteine residues found in the HIV-1 envelope proteins could be aligned with cysteine residues found in the corresponding HIV-2 proteins. However, the HIV-2 proteins were found to contain an additional seven cysteine residues that were found mostly in regions representing insertions relative to HIV-1. Thus, it was concluded that "the folding of the HIV-2 EGP could be different from that of HIV-1, and some regions, therefore, might be exposed in a different manner." No reason was set forth indicating a similar conclusion was not applicable to the TMP proteins of HIV-1 and HIV-2.

Hirsch et al., Cell, 49:307-319 (1987) report the nucleotide sequence of the genome of a STLV-III virus isolated from African green monkeys (STLV-III_{agm}). According to Hirsch et al., the STLV-III_{agm} TMP is 140 amino acids shorter than that of HIV-1 and appears to contain fewer potential glycosylation sites. At the same time, Hirsch et al. describe the STLV-III_{agm} and HIV-1 TMPs as being relatively well conserved, 49% of the amino acids being the same and 32% representing conservative substitutions.

Finally, according to Hirsch et al., the STLV-III_{agm} isolate they examined was virtually identical, by DNA hybridization, to one STLV-III_{agm} isolate but readily distinguishable by restriction

-6-

site mapping from a second STLV-III_{mac} isolate. Thus, the relationship of STLV-III_{mac} to STLV-III_{agm} and HIV-1 is, at present, not well defined.

Brief Summary of the Invention

5 The present invention provides site-directed serological reagents, assay methods and diagnostic kits useful for diagnosing exposure to AIDS-related West African retroviruses (HIV-2 and STLV-III retroviruses). That is, the present invention
10 provides an STLV-III-related polypeptide that immunologically cross-reacts with antibodies induced by HIV-2 infections in humans.

 Thus, the present invention contemplates a STLV-III-related polypeptide defined as consisting
15 essentially of a polypeptide that 1) includes an amino acid residue sequence represented by the formula:

-CAFRQVC-,

 2) contains no more than about 50 amino acid residues, and 3) has the ability to immunoreact with antibodies
20 induced by a HIV-2 retrovirus. Preferably, a STLV-III-related polypeptide contains no more than 33 amino acid residues and has a sequence homologous to a portion of the sequence shown in Figure 1.

 Also contemplated is a method of assaying
25 for the presence of anti-HIV-2 antibodies in a body fluid sample. The method comprises forming an immunoreaction admixture by admixing the sample to be assayed with a STLV-III-related polypeptide of the present invention. The admixture is maintained for a
30 time period sufficient for any anti-HIV-2 antibodies present in the sample to immunoreact with the STLV-III-related polypeptide antigen to form a polypeptide-containing immunoreaction product. Assaying for the presence of any polypeptide-containing immunoreaction

35

-7-

product formed thereby provides a measure of the presence of anti-HIV-2 antibodies in the sample.

Further contemplated by the present invention is a diagnostic system in kit form useful for performing the contemplated assay methods. The system comprises a package that includes a STLV-III-related polypeptide of the present invention present in an amount sufficient to carry out at least one assay.

Preferably, the diagnostic system further includes either a HIV-1-related di-cys polypeptide or a HIV-1-related di-leu polypeptide, or both in an amount sufficient to perform at least one assay for the presence of antibodies to HIV-1. More preferably, HIV-1-related di-cys and di-leu polypeptide are both included in the kit admixed with each other. In another preferred embodiment, a STLV-III-related, HIV-1-related di-cys and HIV-1-related di-leu polypeptide are included in the kit admixed with each other. Most preferred are kits wherein included STLV-III-related and HIV-1-related polypeptides, either separately or in admixture, are operatively affixed to a solid matrix, thereby forming a solid support.

Thus, the present invention provides several benefits and advantages. One benefit provided by the diagnostic systems and methods of this invention is the ability to screen a body fluid such as a blood product for exposure to both of the currently known types of AIDS-related viruses. In addition, because the present invention provides immunological site-specific diagnostic reagents, exposure to HIV-1 versus HIV-2 can be advantageously distinguished.

A further advantage provided by the present invention is that production and use of the contemplated system and methods for diagnosing

-8-

exposure to both the HIV-1 and HIV-2 AIDS causing viruses can now be performed without the necessity or difficulty of producing potentially infectious genetic material as is the case where a viral lysate is used as antigen.

Brief Description of the Drawings

In the Figures forming a portion of the disclosure of this invention:

Figure 1 illustrates a portion of the STLV-III_{mac} TMP amino acid residue sequence. The sequence is shown from left to right and in the direction of amino-terminus to carboxy-terminus in a single-letter code. The residue positions have been numbered as illustrated from 1-33.

Figure 2 illustrates, in a manner similar to Figure 1, a portion of the amino acid residue sequence of the HIV-1 TMP and represent gp41 amino acid residues 589-610 as described in Ratner et al., Nature, 313:277-283 (1985). However, for ease of discussion, those residue positions have been renumbered as illustrated from 1-32.

Figure 3 contains 2 panels illustrating antibody determinations using a diagnostic system of this invention to assay (a) 20 sera from individuals in Guinea-Bissau previously determined to have antibodies against HIV-related viruses (West Africans), (b) 20 sera from HIV-1-infected individuals and (c) 20 sera from blood donors without antibodies to HIV-1 or HIV-2. Sera were considered positive (closed symbols) when they produced optical density (O.D.) values above 0.150 (the mean O.D. of negative samples plus 6 standard deviations). Negative sera are represented by open symbols.

Panel A illustrates the results obtained using a solid support consisting essentially of only

-9-

STLV-III-related polypeptide p80 as target antigen.

Panel B illustrates the results obtained using a solid support consisting essentially of a combination of the HIV-1-related polypeptides (III) and (IV) as target antigen.

Detailed Description of the Invention

A. Definitions

Amino Acid: All amino acid residues identified herein are in the natural L-configuration. In keeping with standard polypeptide nomenclature, J. Biol. Chem., 243:3557-59, (1969), abbreviations for amino acid residues are as shown in the following Table of Correspondence:

15

20

25

30

35

-10-

TABLE OF CORRESPONDENCE

	<u>SYMBOL</u>		<u>AMINO ACID</u>
	<u>1-Letter</u>	<u>3-Letter</u>	
5	Y	Tyr	L-tyrosine
	G	Gly	glycine
	F	Phe	L-phenylalanine
	M	Met	L-methionine
	A	Ala	L-alanine
10	S	Ser	L-serine
	I	Ile	L-isoleucine
	L	Leu	L-leucine
	T	Thr	L-threonine
	V	Val	L-valine
15	P	Pro	L-proline
	K	Lys	L-lysine
	H	His	L-histidine
	Q	Gln	L-glutamine
	E	Glu	L-glutamic acid
20	W	Try	L-tryptophan
	R	Arg	L-arginine
	D	Asp	L-aspartic acid
	N	Asn	L-asparagine
	C	Cys	L-cysteine
25			

It should be noted that all amino acid residue sequences are represented herein by formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a bond to a further sequence of one or more amino acid residues up to a total of about fifty residues in the polypeptide chain.

-11-

Polypeptide and Peptide: Polypeptide and peptide are terms used interchangeably herein to designate a linear series of no more than about 50 amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.

Protein: Protein is a term used herein to designate a linear series of greater than 50 amino acid residues connected one to the other as in a polypeptide.

B. Polypeptides

All of the polypeptides described herein are characterized as including a specific amino acid residue sequence because in each case that particular sequence has been discovered to be capable of immunologically mimicking a linear or continuous antigenic determinant.

In addition, all of the polypeptides of the present invention contain no more than about 50, more usually fewer than about 35 and preferably fewer than about 25 amino acid residues. The specification of an upper limit of amino acid residues included in the subject polypeptides is dictated by and directly dependent on the amount of immunologic site specificity desired and does not, as is well known in the art, reflect the need for any residues other than the specifically identified sequence to form the defined linear antigenic determinant that is useful herein. Thus, while additional amino acid residues included as a sequence flanking a specifically identified sequence would typically reduce site specificity because they impart the ability to form additional linear antigenic determinants, such additional sequences do not prevent formation of the

35

-12-

desired linear antigen determinant that is useful in the present invention.

The peptides of the invention contain at least one cysteine residue, and in certain instances two of such residues. Accordingly, the subject peptides can exist in various oxidative forms. In addition to the monomeric form in which the sulfhydryl group of the cysteine residue(s) is reduced, there can also exist dimeric or polymeric forms in which sulfhydryl groups on two or more peptide molecules become oxidized and form inter- and intrapeptide disulfide bonds. While subject peptides that possess only one cysteine residue can form only linear dimers, those that possess two cysteine residues can form cyclic monomers or linear or cyclic dimers and linear polymers of various lengths. These various oxidative forms are considered part of the subject invention and are included in the terms "polypeptides" and "peptides".

A polypeptide of the present invention can be synthesized by any of the techniques that are known to those skilled in the polypeptide art, including recombinant DNA techniques. Synthetic chemistry techniques, such as a solid-phase Merrifield-type synthesis, are preferred for reasons of purity, antigenic specificity, freedom from undesired side products, ease of production and the like. An excellent summary of the many techniques available can be found in J.M. Steward and J.D. Young, "Solid Phase Peptide Synthesis", W.H. Freeman Co., San Francisco, 1969; M. Bodanszky, et al., "Peptide Synthesis", John Wiley & Sons, Second Edition, 1976 and J. Meienhofer, "Hormonal Proteins and Peptides", Vol. 2, p. 46, Academic Press (New York), 1983 for solid phase peptide synthesis, and E. Schroder and K. Kubke, "The

-13-

Peptides", Vol. 1, Academic Press (New York), 1965 for classical solution synthesis, each of which is incorporated herein by reference. Appropriate protective groups usable in such synthesis are described in the above texts and in J.F.W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, New York, 1973, which is incorporated herein by reference.

In general, these methods comprise the sequential addition of one or more amino acid residues or suitably protected amino acid residues to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid residue is protected by a suitable, selectively removable protecting group. A different, selectively removable protecting group is utilized for amino acids containing a reactive side group such as lysine.

Using a solid phase synthesis as exemplary, the protected or derivatized amino acid is attached to an inert solid support through its unprotected carboxyl or amino group. The protecting group of the amino or carboxyl group is then selectively removed and the next amino acid in the sequence having the complimentary (amino or carboxyl) group suitably protected is admixed and reacted under conditions suitable for forming the amide linkage with the residue already attached to the solid support. The protecting group of the amino or carboxyl group is then removed from this newly added amino acid residue, and the next amino acid (suitably protected) is then added, and so forth. After all the desired amino acids have been linked in the proper sequence, any remaining terminal and side group protecting groups (and solid support) are removed sequentially or concurrently, to afford the final polypeptide.

-14-

1. STLV-III-Related Polypeptides

A STLV-III-related polypeptide of the present invention contains at least 7, preferably at least 12, amino acid residues and includes an amino acid residue sequence represented by the formula:

-CAFRQVC-

In addition, a STLV-III-related polypeptide of the present invention is characterized by its ability to immunoreact with antibodies induced by a HIV-2 TMP, and preferably, induce antibody molecules that immunoreact with native HIV-2 virus.

Preferred STLV-III-related polypeptides contain no more than 33 amino acid residues, have as part of their amino acid residue sequence the sequence -CAFRQVC- and are homologous, preferably without insertion or deletion, and more preferably are identical, to a portion of the sequence shown in Figure 1. Thus, preferred STLV-III-related polypeptides are those consisting essentially of at least 7 amino acid residues and no more than about 50 amino acid residues. From Figure 1 it can be seen that the sequence -CAFRQVC- corresponds in sequence, from left to right and in the direction from amino-terminus to carboxy-terminus, to position 17 through position 23 of the amino acid residue sequence shown in Figure 1. Thus, a preferred polypeptide can include at its amino-terminus zero to 16 contiguous amino acid residues of as shown in Figure 1 from position 1 through position 16, as well as including at its carboxy-terminus zero to 10 contiguous amino acid residues as shown in Figure 1 from position 24 through position 33.

In other words, preferred STLV-III-related polypeptides of the present invention are those defined by the amino acid residue sequence

-15-

represented by the formula:

-BAFRQVB'-;

wherein B is a sequence of amino acid residues
selected from the group consisting of:

5 AIEKYLEDDQAQLNAWGC,
IEKYLEDDQAQLNAWGC,
EKYLEDDQAQLNAWGC,
KYLEDDQAQLNAWGC,
YLEDQAQLNAWGC,
10 LEDQAQLNAWGC,
EDQAQLNAWGC,
DQAQLNAWGC,
QAQLNAWGC,
AQLNAWGC,
15 QLNAWGC,
LNAWGC,
NAWGC,
AWGC,
WGC,
20 GC, and
C; and

wherein B' is a sequence of amino acid residues
selected from the group consisting of:

25 CHTTAVPWPNAS,
CHTTAVPWPNA,
CHTTAVPWP,
CHTTAVPWP,
CHTTAVPW,
CHTTAVP,
30 CHTTAV,
CHTTA,
CHTT,
CHT,
CH, and
35 C.

-16-

In more preferred embodiments, a STLV-III-related polypeptide of the present invention includes an amino acid residue sequence represented by the formula:

5 -AWGCAFRQVC-.

Most preferably, a STLV-III-related polypeptide of the present invention includes an amino acid residue sequence selected from the group consisting of:

10 -AIEKYLEDQAQLNAWCAFRQVC-,
 -AWCAFRQVCHTTVPWPNAS-,
 -AIEKYLEDQAQLNAWGCAFRQVC-,
 -AVEKYLKDQAQLNAWGCAFRQVC-,
 -AIEKYLKDQAQLNSWGCAFRQVC-,
 15 -SWGCAFRQVCHTSVPWVNDT-,
 -AWGCAFRQVCHTTVPWPNAS-,
 -AWGCAFRQVCHITVPWPNAS-, and
 -CAFRQVC-.

20 Most preferred specific STLV-III-related polypeptides include those whose amino acid residue sequences are shown in Table 1.

TABLE 1

<u>Designation</u>	<u>Amino Acid Residue Sequence</u>
25 p80	AIEKYLEDQAQLNAWCAFRQVC
p81	AWCAFRQVCHTTVPWPNAS
p82	AIEKYLEDQAQLNAWGCAFRQVC
p83	AVEKYLKDQAQLNAWGCAFRQVC
p84	AIEKYLKDQAQLNSWGCAFRQVC
30 p85	SWGCAFRQVCHTSVPWVNDT
p86	AWGCAFRQVCHTTVPWPNAS
p87	AWGCAFRQVCHITVPWPNAS
p88	CAFRQVC

35

-17-

It should be understood that a polypeptide of the present invention need not be identical to the amino acid residue sequence of STLV-III TMP (gp32), so long as the subject polypeptides include the required sequence and are able to immunoreact with antibodies induced by a HIV-2 TMP. Therefore, a present STLV-III-related polypeptide can be subject to various changes, such as insertions, and deletions. For example, the glycine residue at position 16 in Figure 1 has been deleted from polypeptides p80 and p81.

Also contemplated are substitutions of one amino acid for another, either conservative or non-conservative, where such changes provide for certain advantages in their use. Conservative substitutions are those where one amino acid residue is replaced by another, biologically similar residue. Examples of conservative substitutions include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another such as between arginine and lysine, between glutamic and aspartic acids or between glutamine and asparagine and the like. The term "conservative substitution" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that such a polypeptide also displays the requisite binding activity.

When a polypeptide of the present invention has a sequence that is not identical to the sequence of a native STLV-III-related TMP because one or more conservative or non-conservative substitutions have been made, usually no more than about 30 number percent, more usually no more than 20 number percent, and preferably no more than 10 number percent of the

-18-

amino acid residues are substituted, except where additional residues have been added at either terminus for the purpose of providing a "linker" by which the polypeptides of this invention can be conveniently
5 affixed to a label or solid matrix, or carrier. Labels, solid matrices and carriers that can be used with the polypeptides of this invention are described hereinbelow.

Amino acid residue linkers are usually
10 at least one residue and can be 40 or more residues, more often 1 to 10 residues. Typical amino acid residues used for linking are tyrosine, cysteine, lysine, glutamic and aspartic acid, or the like. In addition, a polypeptide sequence of this invention can
15 differ from the natural sequence by the sequence being modified by terminal-NH₂ acylation, e.g., acetylation, or thioglycolic acid amidation, by terminal-carboxlyamidation, e.g., with ammonia, methylamine, and the like.

When coupled to a carrier via a linker
20 to form what is known in the art as a carrier-hapten conjugate, a STLV-III-related polypeptide of the present invention is capable of inducing antibodies that immunoreact with a HIV-2 TMP. In view of the
25 well established principle of immunologic cross-reactivity, the present invention therefore contemplates antigenically related variants of the polypeptides shown in Table 1. An "antigenically related variant" is a polypeptide that contains no
30 more than about 50 amino acid residues, includes the amino acid residue sequence -CAFRQVC-, and is capable of inducing antibody molecules that immunoreact with a polypeptide from Table 1 and a HIV-2 TMP.

2. HIV-1-Related Polypeptides

35 In one embodiment, a HIV-1-related di-

cys polypeptide of the present invention contains at least 7, preferably at least 12, amino acid residues and includes an amino acid residue sequence represented by the formula:

-CSGKLIC-.

10 antibodies that immunoreact with native HIV-1.

15 without insertion or deletion, to a portion of the
sequence shown in Figure 2. That is, a preferred HIV-
1-related di-cys polypeptide is one corresponding in
sequence to the sequence shown in Figure 2 from
position 17 to position 23 and including at its amino-
20 terminus a linear, contiguous sequence of 1 to 16
amino acid residues whose sequence is shown in Figure
12 from position 1 through position 16. In addition,
the polypeptide also includes at its carboxy-terminus
a linear, contiguous sequence of 1 to 9 amino acid
25 residues whose sequence is shown in Figure 1 from
position 24 through position 32.

30 represented by the formula:

-JSGCLIJ'-;

wherein J is sequence of amino acid residues selected from the group consisting of:

35

-20-

5 AVERYLKDQQLGIWGC,
 VERYLKDQQLGIWGC,
 ERYLKDQQLGIWGC,
 RYLKDQQLGIWGC,
 YLKDQQLGIWGC,
 LKDQQLGIWGC,
 KDQQLGIWGC,
 10 DQQLGIWGC,
 QQLGIWGC,
 QLLGIWGC,
 LLGIWGC,
 LGIWGC,
 GIWGC,
 15 IWGC,
 WGC,
 GC, and
 C; and

20 wherein J' is a sequence of amino acid residue
 selected from the group consisting of:

CTTAVPWNAS,
 CTTAVPWNA,
 CTTAVPWN,
 CTTAVPW,
 25 CTTAVP,
 CTTAV,
 CTTA,
 CTT,
 CT, and
 30 C.

Preferably, J is IWGC.

Preferred HIV-1-related di-cys
 polypeptides include those whose amino acid residue
 sequences are shown in Table 2.

35

-21-

TABLE 2

Formula	
<u>Designation</u>	<u>Amino Acid Residue Sequence</u>
(I)	CSGKLIC
5 (II)	IWGCSGKLICTTAVP
(III)	IWGCSGKLICTTAVPWNAS
(V)	AVERYLKDQQLLGIWGCSGKLICTTAVPWNAS
(VII)	LLGIWGCSGKLIC
(VIII)	QQLLGIWGCSGKLICTTAVPWNAS
10 (IX)	IWGCSGKLICTTAVPWN
(X)	CSGKLICTTAVPWNAS
(XII)	AVERYLKDQQLLGIWGCSGKLIC
(XIII)	GCSGKLICTTAVPWN

15

The present invention further contemplates the discovery that recognition of antibodies to HIV-1 in immunological assays is significantly enhanced if the above described HIV-1-related di-cys polypeptides are used in combination with a second HIV-1-related polypeptide, designated a di-leu polypeptide.

20 HIV-1-related di-leu polypeptides consist essentially of at least 15 amino acid residues and include an amino acid residue sequence represented by the formula:

-ZLLG(X)WZ'-,

wherein X is selected from the group consisting of I, L, M or F;

30

wherein Z is selected from the amino acid residue sequence of the HIV-1 virus gp41 protein immediately adjacent to the amino-terminal side of the L-leucine residue in the 599th position of the gp41 protein (amino acid residue 11 of Figure 2);

35

-22-

wherein Z' is selected from the amino acid residue sequence of the HIV-1 virus gp41 protein immediately adjacent to the carboxy side of the L-tryptophan residue in the 603rd position of the gp41 protein (amino acid residue 15 of Figure 2); and

wherein one of Z or Z' may be zero residues long and wherein Z and Z' together comprise at least ten residues.

Preferred HIV-1-related di-leu polypeptides contain no more than 32 amino acid residues, have as a portion of their sequence the sequence represented by the formula:

-ZLLG(X)WZ'-,

and are, except when X is other than I, homologous to a portion of the sequence shown in Figure 2. Thus, in preferred embodiments, Z is a linear, contiguous sequence of 1 to 10 amino acid residues whose sequence is shown in Figure 2 from position 1 to position 10, and Z' is a linear contiguous sequence of 1 to 17 amino acid residues whose sequence is shown in Figure 2 from position 16 to 32. In other words, in preferred embodiments, Z is a sequence of amino acid residues selected from the group consisting of:

AVERYLKDQQ,
 25 VERYLKDQQ,
 ERYLKDQQ,
 RYLKDQQ,
 YLKDQQ,
 LKDQQ,
 30 KDQQ,
 DQQ,
 QQ, and
 Q; and

Z' is a sequence of amino acid residues selected from the group consisting of:

-23-

5 GCSGKLICTTAVPWNAS,
 GCSGKLICTTAVPWNA,
 GCSGKLICTTAVPWN,
 GCSGKLICTTAVPW,
 GCSGKLICTTAVP,
 GCSGKLICTTAV,
 GCSGKLICTTA,
 GCSGKLICTT,
 GCSGKLICT,
 10 GCSGKLIC,
 GCSGKLI,
 GCSGKL,
 GCSGK,
 GCSG,
 15 GCS,
 GC, and
 G.

It should be noted that X corresponds
 to position 602 of the TMP (gp41) protein of HIV-1,
 20 and when X is I, the included sequence corresponds in
 amino acid residue sequence of the HIV-1 TMP protein
 from position 598 to position 604 i.e., position 10 to
 position 16 of the polypeptide shown in Figure 2. On
 the other hand, it is believed that based on a study
 25 of various TMP amino acid residue sequences obtained
 from different HIV-1 isolates, the substitution for I
 at position 602 with L, M or F results in an
 antigenically equivalent polypeptide.

Preferred HIV-I related di-leu
 30 polypeptides include those whose amino acid residue
 sequences are shown in Table 3.

35

-24-

TABLE 3

<u>Formula Designation</u>	<u>Amino Acid Residue Sequence</u>
(IV)	AVERYLKDQQLGIWGCSGKLI
5 (VI)	LKDQQLGIWGCSGLKI
(XIV)	LKDQQLGIWGCSGK
(XV)	RILAVERYLKDQQLGIWGCS

10 Preferred combinations of HIV-1-related di-cys and di-leu polypeptides include (IV) or (XII) with (III), (XIII), or (X). The combinations of (III) with (IV) and (XIII) with (IV) being particularly preferred the combinations.

15 In another embodiment, the present invention contemplates a HIV-1-related polypeptide having an amino acid residue sequence represented by the formula, designated formula (XI):

SGKLICTTAVPWNAS.

20 In view of the results discussed in the Examples, it is clear that a significant antigenic determinant of the HIV-1 virus which reacts with HIV-1 induced antibodies is defined by (contained within) the seven amino acid residue sequence of formula (I) described before. Moreover, even though each of the
25 HIV-1-related polypeptides of the present invention reacts with most HIV-1 positive sera, individual patient sera have been observed to react specifically with one of the HIV-1-related peptides but not
30 another. This observation indicates that additional antigenic determinants exist in longer peptides containing the sequence of formula (I), such as those peptides shown in Table 2. It is well within the skill of an ordinary worker in the peptide synthesis
35 art to prepare fragments of the HIV-1-related peptides.

-25-

to determine antigenic and immunogenic fragments within them. Accordingly, such antigenic and immunogenic fragments can be used in the diagnostic systems and methods of the present invention.

5 Moreover, one of skill would also recognize that longer peptides corresponding to a portion of the HIV-1 TMP protein and conforming to the teachings herein would function in the assay methods and systems of the present invention.

10 C. Inocula

In another embodiment, a STLV-III-related polypeptide of this invention or an antigenically related variant thereof is used in a pharmaceutically acceptable aqueous diluent composition to form an
15 inoculum that, when administered in an effective amount, is capable of inducing antibodies that immunoreact with STLV-III and HIV-2.

The word "inoculum" in its various grammatical forms is used herein to describe a
20 composition containing a polypeptide of this invention as an active ingredient used for the preparation of antibodies against HIV-2. When a polypeptide is used to induce antibodies it is to be understood that the polypeptide can be used alone, or linked to a carrier
25 as a conjugate, or as a polypeptide polymer, but for ease of expression the various embodiments of the polypeptides of this invention are collectively referred to herein by the term "polypeptide", and its various grammatical forms.

30 For a polypeptide that contains fewer than about 35 amino acid residues, it is preferable to use the peptide bound to a carrier for the purpose of inducing the production of antibodies as already noted.

35

-26-

As also already noted, one or more additional amino acid residues can be added to the amino- or carboxy-termini of the polypeptide to assist in binding the polypeptide to a carrier. Cysteine residues added at the amino- or carboxy-termini of the polypeptide have been found to be particularly useful for forming conjugates via disulfide bonds. However, other methods well known in the art for preparing conjugates can also be used. Exemplary additional linking procedures include the use of Michael addition reaction products, di-aldehydes such as glutaraldehyde, Klipstein et al., J. Infect. Dis., 147, 318-326 (1983) and the like, or the use of carbodiimide technology as in the use of a water-soluble carbodiimide to form amide links to the carrier. For a review of protein conjugation or coupling through activated functional groups, see Aurameas, et al., Scand. J. Immunol., Vol. 8, Supp-1, 7, 7-23 (1978).

Useful carriers are well known in the art, and are generally proteins themselves. Exemplary of such carriers are keyhole limpet hemocyanin (KLH), edestin, thyroglobulin, albumins such as bovine serum albumin (BSA) or human serum albumin (HSA), red blood cells such as sheep erythrocytes (SRBC), tetanus toxoid, cholera toxoid as well as polyamino acids such as poly (D-lysine: D-glutamic acid), and the like.

The choice of carrier is more dependent upon the ultimate use of the inoculum and is based upon criteria not particularly involved in the present invention. For example, a carrier that does not generate an untoward reaction in the particular animal to be inoculated should be selected.

The present inoculum contains an effective, immunogenic amount of a polypeptide of this invention,

-27-

typically as a conjugate linked to a carrier. The effective amount of polypeptide per unit dose depends, among other things, on the species of animal inoculated, the body weight of the animal and the chosen inoculation regimen as is well known in the art. Inocula typically contain polypeptide concentrations of about 10 micrograms to about 500 milligrams per inoculation (dose), preferably about 50 micrograms to about 50 milligrams per dose.

The term "unit dose" as it pertains to the inocula of the present invention refers to physically discrete units suitable as unitary dosages for animals, each unit containing a predetermined quantity of active material calculated to produce the desired immunogenic effect in association with the required diluent; i.e., carrier, or vehicle. The specifications for the novel unit dose of an inoculum of this invention are dictated by and are directly dependent on (a) the unique characteristics of the active material and the particular immunologic effect to be achieved, and (b) the limitations inherent in the art of compounding such active material for immunologic use in animals, as disclosed in detail herein, these being features of the present invention.

Inocula are typically prepared from the dried solid polypeptide-conjugate by dispersing the polypeptide-conjugate in a physiologically tolerable (acceptable) diluent such as water, saline or phosphate-buffered saline to form an aqueous composition.

Inocula can also include an adjuvant as part of the diluent. Adjuvants such as complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA) and alum are materials well known in the art, and are available commercially from several sources.

-26-

D. Antibodies and Antibody Compositions

The term "antibody" in its various grammatical forms is used herein to refer to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antibody combining site or paratope. Exemplary antibody molecules are intact immunoglobulin molecules, substantially intact immunoglobulin molecules, and those portions of an immunoglobulin molecule that contain the paratope, including those portions known in the art as Fab, Fab', F(ab')₂ and F(v).

An antibody composition of the present invention is characterized as containing antibody molecules that immunoreact with HIV-2 TMP and a STLIII-related polypeptide of this invention, but is substantially free of antibodies that immunoreact with any other HIV-2-related protein.

An antibody composition of the present invention is typically produced by immunizing a laboratory mammal with an inoculum of the present invention and to thereby induce in the mammal antibody molecules having the appropriate polypeptide immunospecificity. The antibody molecules are then collected from the mammal and isolated to the extent desired by well known techniques such as, for example, by immunoaffinity chromatography. The antibody composition so produced can be used in, inter alia, the diagnostic methods and systems of the present invention to detect HIV-2 in a body sample.

The antibody compositions of this invention induced by a polypeptide of this invention, including an oligomeric polypeptide and a polypeptide polymer, can be described as being oligoclonal as compared to naturally occurring polyclonal antibodies since they

are raised to an immunogen (the relatively small polypeptide) having relatively few epitopes as compared to the epitopes mimicked by an intact HIV-2 TMP molecule. Consequently, receptors of this invention bind to epitopes of the polypeptide, whereas naturally occurring antibodies raised to the whole TMP molecule bind to epitopes throughout the TMP molecule and are referred to as being polyclonal.

Monoclonal antibody compositions are also contemplated by the present invention. A monoclonal antibody composition contains, within detectable limits, only one species of antibody combining site capable of effectively binding HIV-2 TMP. Thus, a monoclonal antibody composition of the present invention typically displays a single binding affinity for HIV-2 TMP even though it may contain antibodies capable of binding proteins other than HIV-2 TMP.

Suitable antibodies in monoclonal form, typically whole antibodies, can also be prepared using hybridoma technology described by Niman et al., Proc. Natl. Sci. U.S.A., 80:4949-4953 (1983), which description is incorporated herein by reference. Briefly, to form the hybridoma from which the monoclonal antibody composition is produced, a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with a polypeptide of this invention.

It is preferred that the myeloma cell line be from the same species as the lymphocytes. Typically, a mouse of the strain 129 Glx⁺ is the preferred mammal. Suitable mouse myelomas for use in the present invention include the hypoxanthine-aminopterin-thymidine-sensitive (HAT) cell lines P3X63-Ag8.653, and Sp2/0-Ag14 that are available from the American Type Culture Collection, Rockville, MD,

-30-

under the designations CRL 1580 and CRL 1581, respectively.

Splenocytes are typically fused with myeloma cells using polyethylene glycol (PEG) 1500. Fused hybrids are selected by their sensitivity to HAT. Hybridomas secreting the receptor molecules of this invention are identified using the enzyme linked immunosorbent assay (ELISA) described in Example 11.

A monoclonal antibody composition of the present invention can be produced by initiating a monoclonal hybridoma culture comprising a nutrient medium containing a hybridoma that secretes antibody molecules of the appropriate polypeptide specificity. The culture is maintained under conditions and for a time period sufficient for the hybridoma to secrete the antibody molecules into the medium. The antibody-containing medium is then collected. The antibody molecules can then be further isolated by well known techniques.

Media useful for the preparation of these compositions are both well known in the art and commercially available and include synthetic culture media, inbred mice and the like. An exemplary synthetic medium is Dulbecco's minimal essential medium (DMEM; Dulbecco et al., Virology 8:396 (1959)) supplemented with 4.5 gm/l glucose, 20 mm glutamine, and 20% fetal calf serum. An exemplary inbred mouse strain is the Balb/c.

The monoclonal antibody compositions produced by the above method can be used, for example, in diagnostic and therapeutic modalities wherein formation of an HIV-2 TMP-containing immunoreaction product is desired.

E. Diagnostic Systems

A diagnostic system in kit form of the

-31-

present invention includes, in an amount sufficient for at least one assay, a polypeptide, antibody composition or monoclonal antibody composition of the present invention, as a packaged reagent.

5 Instructions for use of the packaged reagent are also typically included.

As used herein, the term "package" refers to a solid matrix or material such as glass, plastic, paper, foil and the like capable of holding within
10 fixed limits a polypeptide, antibody composition or monoclonal antibody composition of the present invention. Thus, for example, a package can be a glass vial used to contain milligram quantities of a contemplated polypeptide or it can be a microtiter
15 plate well to which microgram quantities of a contemplated polypeptide have been operatively affixed, i.e., linked so as to be capable of being immunologically bound by an antibody.

"Instructions for use" typically include a
20 tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer
25 conditions and the like.

In preferred embodiments, a diagnostic system of the present invention further includes a label or indicating means capable of signaling the formation of a complex containing a polypeptide or
30 antibody molecule of the present invention.

The word "complex" as used herein refers to the product of a specific binding reaction such as an antibody-antigen or receptor-ligand reaction. Exemplary complexes are immunoreaction products.

35

-32-

As used herein, the terms "label" and "indicating means" in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate the presence of a complex. Any label or indicating means can be linked to or incorporated in an expressed protein, polypeptide, or antibody molecule that is part of an antibody or monoclonal antibody composition of the present invention, or used separately, and those atoms or molecules can be used alone or in conjunction with additional reagents. Such labels are themselves well-known in clinical diagnostic chemistry and constitute a part of this invention only insofar as they are utilized with otherwise novel proteins methods and/or systems.

The labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer. Suitable fluorescent labeling agents are fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyanate (FITC), 5-dimethylamine-1-naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRITC), lissamine, rhodamine 8200 sulphonyl chloride (RB 200 SC) and the like. A description of immunofluorescence analysis techniques is found in DeLuca, "Immunofluorescence Analysis", in Antibody As a Tool, Marchalonis, et al., eds., John Wiley & Sons, Ltd., pp. 189-231 (1982), which is incorporated herein by reference.

In preferred embodiments, the indicating group is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, or the like. In such cases

-33-

where the principal indicating group is an enzyme such as HRP or glucose oxidase, additional reagents are required to visualize the fact that a receptor-ligand complex (immunoreactant) has formed. Such additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as diaminobenzidine. An additional reagent useful with glucose oxidase is 2,2'-azino-di-(3-ethyl-benzthiazoline-G-sulfonic acid) (ABTS).

Radioactive elements are also useful labeling agents and are used illustratively herein. An exemplary radiolabeling agent is a radioactive element that produces gamma ray emissions. Elements which themselves emit gamma rays, such as ^{124}I , ^{125}I , ^{128}I , ^{132}I and ^{51}Cr represent one class of gamma ray emission-producing radioactive element indicating groups. Particularly preferred is ^{125}I . Another group of useful labeling means are those elements such as ^{11}C , ^{18}F , ^{15}O and ^{13}N which themselves emit positrons. The positrons so emitted produce gamma rays upon encounters with electrons present in the animal's body. Also useful is a beta emitter, such as ^{111}In of ^3H .

The linking of labels, i.e., labeling of, polypeptides and proteins is well known in the art. For instance, antibody molecules produced by a hybridoma can be labeled by metabolic incorporation of radioisotope-containing amino acids provided as a component in the culture medium. See, for example, Galfre et al., Meth. Enzymol., 73:3-46 (1981). The techniques of protein conjugation or coupling through activated functional groups are particularly applicable. See, for example, Aurameas, et al., Scand. J. Immunol., Vol. 8 Suppl. 7:7-23 (1978),

35

-34-

Rodwell et al., Biotech., 3:889-894 (1984), and U.S. Pat. No. 4,493,795.

The diagnostic systems can also include, preferably as a separate package, a specific binding agent. A "specific binding agent" is a molecular entity capable of selectively binding a reagent species of the present invention or a complex containing such a species, but is not itself a polypeptide or antibody molecule composition of the present invention. Exemplary specific binding agents are second antibody molecules, complement proteins or fragments thereof, S. aureus protein A, and the like. Preferably the specific binding agent binds the reagent species when that species is present as part of a complex.

In preferred embodiments, the specific binding agent is labeled. However, when the diagnostic system includes a specific binding agent that is not labeled, the agent is typically used as an amplifying means or reagent. In these embodiments, the labeled specific binding agent is capable of specifically binding the amplifying means when the amplifying means is bound to a reagent species-containing complex.

The diagnostic kits of the present invention can be used in an "ELISA" format to detect the presence or quantity of at least anti-HIV-2 antibodies in a body fluid sample such as serum, plasma or urine. "ELISA" refers to an enzyme-linked immunosorbent assay that employs an antibody or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of an antigen or antibody present in a sample. A description of the ELISA technique is found in Chapter 22 of the 4th Edition of Basic and Clinical

-35-

Immunology by D.P. Sites et al., published by Lange Medical Publications of Los Altos, CA in 1982 and in U.S. Patents No. 3,654,090; No. 3,850,752; and No. 4,016,043, which are all incorporated herein by
5 reference.

Thus, in preferred embodiments, a polypeptide, antibody molecule composition or monoclonal antibody molecule composition of the present invention can be affixed to a solid matrix to
10 form a solid support that comprises a package in the subject diagnostic systems.

The reagent is typically affixed to the solid matrix by adsorption from an aqueous medium although other modes of affixation, well known to
15 those skilled in the art, can be used.

Useful solid matrices are also well known in the art. Such materials are water insoluble and include the cross-linked dextran available under the trademark SEPHADEX from Pharmacia Fine Chemicals
20 (Piscataway, NJ); agarose; beads of polystyrene beads about 1 micron to about 5 millimeters in diameter available from Abbott Laboratories of North Chicago, IL; polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose- or nylon-based webs
25 such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.

The reagent species, labeled specific binding agent or amplifying reagent of any diagnostic
30 system described herein can be provided in solution, as a liquid dispersion or as a substantially dry power, e.g., in lyophilized form. Where the indicating means is an enzyme, the enzyme's substrate can also be provided in a separate package of a
35 system. A solid support such as the before-described

-36-

microtiter plate and one or more buffers can also be included as separately packaged elements in this diagnostic assay system.


The packaging materials discussed herein in relation to diagnostic systems are those customarily utilized in diagnostic systems. Such materials include glass and plastic (e.g., polyethylene, polypropylene and polycarbonate) bottles, vials, plastic and plastic-foil laminated envelopes and the like.

In one embodiment a diagnostic system of the present invention is useful for assaying for the presence of antibodies induced by HIV-2. Such a system comprises, in kit form, a package containing a STLV-III-related polypeptide of this invention. Preferably, the included STLV-III-related polypeptide contains no more than 33 amino acid residues and has a sequence homologous to a portion of the sequence shown in Figure 1. More preferably, the polypeptide is p80, p81, p82, p83, p84, p85, p86, p87, p88, or p89, most preferably p82 and/or p86, all of whose sequences are shown in Table 1.

When it is desired to provide a diagnostic system capable of being used to detect and distinguish between exposure to HIV-1 and HIV-2, a HIV-1-related di-cys or di-leu polypeptide as described herein is included along with a STLV-III-related polypeptide in the kit. Preferred HIV-1-related di-cys polypeptides included in the kit are those that contain no more than 32 amino acid residues, have as a portion of their sequence the sequence -CSGKLIC- and are homologous to a portion of the sequence shown in Figure 2. More preferably, an included HIV-1-related di-cys polypeptide has a sequence selected from the group shown in Table 2.

-37-

In another embodiment of a diagnostic system capable of being used to detect and distinguish between anti-HIV-1 and anti-HIV-2 antibodies, a HIV-1-related di-leu polypeptide of this invention is included in the kit, in addition to the STLIV-III-related polypeptide. Preferred HIV-1-related di-leu polypeptides included in the kit are those that contain no more than 32 amino acid residues, have as a portion of their sequence the sequence represented by the formula:



and are, except when X is other than I, homologous to a portion of the sequence shown in Figure 2. More preferably, the HIV-1-related di-leu polypeptide has a sequence selected from the group shown in Table 3.

In view of the finding that a combination, in admixture, of HIV-1 di-cys and di-leu polypeptides of the present invention unexpectedly allows for an increased ability to detect exposure to HIV-1, a diagnostic system comprising a package that includes a STLIV-III-related polypeptide of this invention and a combination, in admixture, of a HIV-1 di-cys and a HIV-1 di-leu polypeptide is also contemplated.

In one embodiment, the STLIV-III-related polypeptide and HIV-1-related polypeptide combination are physically separated within the kit thereby allowing for distinguishing between the presence of anti-HIV-1 and HIV-2 antibodies. An exemplary kit of this type includes a first solid support comprised of microtiter plate wells coated with, i.e., having operatively affixed thereto, a STLIV-III-related polypeptide, preferably p82 and/or p86, and a second solid support comprised of microtiter plate wells coated with, i.e., having operatively affixed thereto an admixture of HIV-1-related polypeptides (III) and

-38-

(IV). Of course, the STLV-III and HIV-1 polypeptide coated wells can be on the same or different plates.

In another embodiment, the STLV-III-related, HIV-1-related di-cys and HIV-1-related di-leu polypeptides are included in the kit as an admixture of all three, thereby creating the ability to screen for exposure to a greater range of AIDS-related viruses using one solid support. A kit of this type typically comprises a solid support such as a microtiter plate having operatively affixed thereto in an individual well, an admixture of STLV-III-related polypeptide, preferably p82 and/or p86, HIV-1-related di-cys polypeptide (III) and HIV-1-related di-leu polypeptide (IV).

15 F. Assay Methods

The present invention contemplates a method for detecting the presence and preferably amount of antibodies against HIV-2 (AIDS-related West African retroviruses) in a body fluid sample by producing a complex containing a polypeptide of the present invention and such antibodies. Those skilled in the art will understand that there are numerous well known clinical diagnostic chemistry procedures that can be utilized to form those complexes. Thus, while exemplary assay methods are described herein, the invention is not so limited.

Various heterogeneous and homogeneous assay protocols can be employed, either competitive or non-competitive, for detecting the presence, and preferably amount, of antibodies against HIV-2 TMP in a body fluid sample using the STLV-III-related polypeptides of this invention. For example, the present invention contemplates a method for assaying a body sample for the presence of anti-HIV-2 antibodies comprising the steps of:

-39-

(a) Admixing a body fluid sample with a STLV-III-related polypeptide of the present invention, preferably p82 and/or p86, thus forming an immunoreaction admixture. Preferably, the body fluid sample is provided as a known amount of blood or a blood derived product such as serum or plasma, although urine, saliva, semen, vaginal secretion or cerebral-spinal fluid (CSF) can also be used. Preferably the HIV-2-related polypeptide is present as part of a solid support, e.g., a HIV-2 related polypeptide of the present invention affixed to the inner walls of microtiter plate well, so that the immunoreaction admixture formed has a solid and a liquid phase.

(b) Maintaining the admixture under biological assay conditions for a predetermined time period such as about 10 minutes to about 16-20 hours at a temperature of about 4 degrees C to about 45 degrees C that is sufficient for any anti-HIV-2 antibodies present in the sample to immunoreact with (immunologically bind) the polypeptide to form a polypeptide-containing immunoreaction product.

Biological assay conditions are those that maintain the biological activity of the polypeptide molecules of this invention and the anti-HIV-2 antibodies sought to be assayed, and include a temperature range of about 4 degrees C to about 45 degrees C, a pH value range of about 5 to about 9 and an ionic strength varying from that of distilled water to that of about one molar sodium chloride. Methods for optimizing such conditions are well known in the art.

(c) Assaying for the presence of any polypeptide-containing immunoreaction product that

35

-40-

formed, and thereby the presence of any anti-HIV-2 antibodies in the immunoreaction admixture is also determined. Preferably, the amount of any polypeptide-containing immunoreaction product formed is determined, and thereby the amount of anti-HIV-2 antibodies present in the sample.

Assaying for the presence of any polypeptide-containing (anti-HIV-2 antibody-containing) immunoreaction product, either directly or indirectly, can be accomplished by assay techniques well known in the art. For instance, in preferred embodiments, the polypeptide-containing immunoreaction product of step (b) is further prepared for assaying according to step (c) by the following steps:

(i) Admixing a biologically active labeled specific binding agent with the polypeptide-containing immunoreaction product to form a labeling-reaction admixture. The labeled specific binding agent is capable of binding to any immunoglobulin present in the polypeptide-containing immunoreaction product to form a labeled complex. Preferably, the labeled specific binding agent is comprised of second antibody molecules such as xenogeneic anti-human Fc antibodies. More preferably, the labeled specific binding reagent is immunoglobulin class specific.

(ii) The labeling-reaction admixture so formed is maintained under biological assay conditions for a predetermined time period sufficient for the labeled specific binding agent to bind to any anti-HIV-2 antibodies present as polypeptide-containing immunoreaction product to form a labeled complex.

Assaying for the presence of the labeled complex provides an assay for the presence of anti-HIV-2 antibodies in the sample. In preferred

-41-

embodiments, the amount of the labeled specific binding agent bound as part of the complex is determined, and thereby the presence and amount of anti-HIV-2 antibodies in the sample can be determined. That amount can be zero, thereby indicating no anti-HIV-2 antibodies are present in the sample, within the limits that can be detected. Methods for assaying for the presence and amount of a labeled specific binding agent depend on the label used, such labels and assay methods being well known in the art.

Alternatively, homogeneous assay methods such as those described in U.S. Patents No. 4,536,479; No. 4,233,401; No. 4,233,402 and No. 3,996,345, whose disclosures are incorporated herein by reference, can be used to detect the polypeptide-containing immunoreaction product of step (c).

Examples

The following examples are intended to illustrate, but not limit, the present invention.

1. Synthesizing HTLV-III Peptide (II)

A. Synthesis of Boc-Proline Resin:

Chloromethylated styrene-divinylbenzene polymer containing 1.3 molar equivalents (meq) chloride/gram of resin was esterified with Boc-proline in anhydrous N,N-Dimethylformamide (DMF) using potassium iodide (KI) as the catalytic agent. The reaction was carried out at 55°C for 24 hours as described by Steward & Young, "Solid Phase Peptide Synthesis", 2nd edition (1984), Pierce Chemical Co. The substitution of Boc-proline was 0.92 mMole/gram as determined using a picric acid assay on a portion of deblocked resin.

B. Synthesis and Characterization of Peptide (II).

Synthesis of peptide of formula (II)

-42-

was accomplished using the technique of Merrifield, J. Am. Chem. Soc., 85:2149-54 (1963). The peptide sequence IWGCSGKLICTTAVP was synthesized on a Vega 250C automated peptide synthesizer using a double couple program. Boc-proline resin (1.8326 g) was sequentially double coupled with the following Boc-L-amino acids obtained from Bachem. Inc., Torrence, CA, in twelve meq excess:

10	<u>Amino Acid</u>	<u>Solvent</u>
	Boc-Val	CH ₂ Cl ₂
	Boc-Ala	CH ₂ Cl ₂
	Boc-(O-Bzl)-Thr	CH ₂ Cl ₂
	Boc-(O-Bzl)-Thr	CH ₂ Cl ₂
15	Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
	Boc-Ile	CH ₂ Cl ₂
	Boc-Leu	10% DMF/CH ₂ Cl ₂
	Box-(Cl-Z)-Lys	CH ₂ Cl ₂
	Boc-Gly	CH ₂ Cl ₂
20	Boc-(O-Bxl)-Ser	CH ₂ Cl ₂
	Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
	Boc-Gly	CH ₂ Cl ₂
	Boc-Trp	10% DMF/CH ₂ Cl ₂
	Boc-Ile	CH ₂ Cl ₂

25

In the above sequential addition protocol, "Boc" is used as a chemical abbreviation for the tert-butyloxycarbonyl alpha-amino protecting group. The functional group is removed by hydrolysis in 50% trifluoroacetic acid (TFA)/50% dichloromethane (CH₂Cl₂) after the amino acid has been coupled to the growing peptide chain. This action exposes the amino terminus of the chain to allow the next amino acid to be effectively coupled.

35

-43-

In addition to the Boc protecting group on every amino acid, the side chains of some amino acids are further protected from reaction by the chemistry of peptide synthesis. These protecting groups, listed in parentheses on the foregoing sequential addition list, are all stable to the conditions of peptide synthesis, yet are easily removed from the amino acid during cleavage in hydrofluoric acid. Anisole (methylphenyl ether) acts as a nucleophilic scavenger during the HF cleavage step to prevent alkylation of the peptide by the liberated protecting group carbonium ions. The protecting groups for the amino acids listed are defined below:

O-Benzyl: Benzyl-ester; attached to the hydroxyl side chain of both serine and threonine to prevent the acylation or branching of the peptide chain.

MeObzl: 4-Methoxybenzyl; attached to the sulfhydryl group of cysteine to prevent its oxidation during peptide synthesis.

Cl-Z: 2-chlorobenzyloxycarbonyl; attached to the alpha-amino group of lysine to prevent the formation of side chain growth from this site on the peptide.

The peptide was cleaved from the resin with 10% anisole in hydrofluoric acid and extracted with 20% aqueous acetic acid. This solution was filtered to remove solid resin and run through a Fractogel TSK HW-40F desalting column using an eluent of 20% aqueous acetic acid. Fractions were collected in 10 ml aliquots and the column effluent was monitored at 280 nanometers (nm). Fractions showing positive absorbance at 280 nm were diluted with 0.1% trifluoroacetic acid (TFA) in water and analyzed by

-44-

high performance liquid chromatography (HPLC) using the following analytical HPLC conditions:

Buffer A: 0.1% TFA/distilled deionized water;

Buffer B: 0.1% TFA/HPLC grade acetonitrile;

Gradient Conditions: 10% buffer 'B' to 50% buffer 'B' in buffer "A" over 20 minutes;

Wavelength: 214 nm;

Flow: 1.0 ml/minute (min);

Column: Vydac 214TP54 C-4 Protein column, 250 X 4.5 mm.

The major peak of absorbance at 214 nm was determined to have a retention time of 12.42 min. The Fractogel fractions that contained greater than 70% of this peak were pooled and labeled Fr:1. The Fractogel fractions that contained less than 70% but greater than 50% of this peak were pooled and labeled Fr:2..

Analytical HPLC on Fr:1 showed the 12.42 min peak to constitute 87% of the total area. Fr:1 was further characterized by amino acid analysis using a model 4150 Alpha Amino Acid Analyzer, LKB Instruments, Inc. Gaithersburg, MD, amino acid residue sequence determination using a model 470 A Protein sequencer, Applied Biosystems, Foster City, CA,, and determination of % peptide content as determined from the recovery on amino acid analysis of a known amount of peptide. Peptide sequence analysis was also performed on the peptide-resin to confirm the expected sequence of the peptide.

C. Polymerization of the Peptide of Formula (II):

The peptide contained in the Fr:1 pool described in part B was lyophilized to remove acetic acid and solubilized at 200 ug/ml in 0.1 M sodium

-45-

bicarbonate buffer pH 9.0. Aliquots of this peptide diluted to 20 micrograms per milliliter (ug/ml) in sodium bicarbonate buffer were used to coat microtiter walls for ELISAs shown in Table 4. For assays shown
5 below in Tables 4-6, the peptide was solubilized in water at 10 milligrams per milliliter (ug/ml) and diluted in phosphate buffer pH 7.3 to 5 ug/ml for coating microtiter wells.

The peptide in Fr:1 exists primarily in
10 a single form that is believed to be unoxidized monomer. Because the peptide of formula (II) contains two cysteines, however, it polymerizes in the presence of air upon solubilization in neutral or basic aqueous buffer.

The peptide used in ELISAs described
15 below is a mixture of very small amounts of linear monomer, and larger amounts of cyclic monomer (formed by intrapolypeptide disulfide bonding) and even larger amounts of polymers (formed by interpolypeptide
20 disulfide bonding) of various sizes. Without wishing to be bound thereby, applicants believe that the polymer forms are important for the reactivities described herein. The cyclic monomer form, while retaining a portion of the antigenicity of the polymer
25 form, is believed to be less efficient in binding to the microtiter wells and is less suited as the solid phase component of the ELISA. The presumed cyclic monomer is revealed as a sharp peak at about 12.7 min retention time in HPLC analysis while the polymer is
30 characterized as a broad peak at approximately 15.9 min retention time.

Oxidation conditions can be altered
with respect to temperature, pH, peptide
concentration, and the like as known to those skilled
35 in the art to alter the proportion of monomer, cyclic

-46-

monomer and polymer remaining in the preparation, or the size of polymers formed. Small amounts of so called deletion peptides (lacking one or more amino acids) and their oxidation forms can also be found in the peptide preparations used in the ELISA but these minor impurities do not affect the use of the peptide.

2. Synthesis and Characterization of HIV-1 Polypeptides (III) through (XI):

Synthesis of these peptides was accomplished using substantially the same classical Merrifield technique as described earlier for peptide (II). For peptide (III), Boc-serine resin with substitution of 0.92 mMole/gram was used. For peptide (IV), Boc-isoleucine resin with substitution of 0.8 mMole/gram was used. Synthesis of the Boc-serine and Boc-isoleucine resins was accomplished by the Gisin method as described by Stewart & Young, supra.

A. For peptide (III) the amino acid residue sequence IWGCSGKLICTTAVPWNAS was synthesized using the following Boc-L-amino acids in 12 meq excess:

	<u>Amino Acid</u>	<u>Solvent</u>
	Boc-Ala	CH ₂ Cl ₂
25	Boc-Asn/Hobt	DMF
	Boc-Trp	10% DMF/CH ₂ Cl ₂
	Boc-Pro	CH ₂ Cl ₂
	Boc-Val	CH ₂ Cl ₂
	Boc-Ala	CH ₂ Cl ₂
30	Boc-(O-Bzl)-Thr	CH ₂ Cl ₂
	Boc-(O-Bzl)-Thr	CH ₂ Cl ₂
	Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
	Boc-Ile	CH ₂ Cl ₂
	Boc-Leu	10% DMF/CH ₂ Cl ₂
35	Boc-(Cl-Z)-Lys	CH ₂ Cl ₂

-47-

	<u>Amino Acid</u>	<u>Solvent</u>
	Boc-Gly	CH ₂ Cl ₂
	Boc-(O-Bzl)-Ser	CH ₂ Cl ₂
	Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
5	Boc-Gly	CH ₂ Cl ₂
	Boc-Trp	10% DMF/CH ₂ Cl ₂
	Boc-Ile	CH ₂ Cl ₂

10 B. For peptide (IV) the peptide sequence AVERYLKDQQLGIWGCSGLKI was synthesized using the following Boc-L-amino acids in 12 meq excess:

	<u>Amino Acid</u>	<u>Solvent</u>
	Boc-Leu	10% DMF/CH ₂ Cl ₂
15	Boc-(Cl-Z)-Lys	CH ₂ Cl ₂
	Boc-Gly	CH ₂ Cl ₂
	Boc-(O-Bzl)-Ser	CH ₂ Cl ₂
	Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
	Boc-Gly	CH ₂ Cl ₂
20	Boc-Trp	10% DMF/CH ₂ Cl ₂
	Boc-Ile	CH ₂ Cl ₂
	Boc-Gly	CH ₂ Cl ₂
	Boc-Leu	10% DMF/CH ₂ Cl ₂
	Boc-Leu	10% DMF/CH ₂ Cl ₂
25	Boc-Gln/Hobt	DMF
	Boc-Gln/Hobt	DMF
	Boc-(Bzl)-Asp	CH ₂ Cl ₂
	Boc-(Cl-Z)-Lys	CH ₂ Cl ₂
	Boc-Leu	10% DMF/CH ₂ Cl ₂
30	Boc-(Br-Z)-Tyr	CH ₂ Cl ₂
	Boc-(Tosyl)-Arg	10% DMF/CH ₂ Cl ₂
	Boc-(Bzl)-Blu	CH ₂ Cl ₂
	Boc-Val	CH ₂ Cl ₂
	Boc-Ala	CH ₂ Cl ₂
35		

-48-

As with peptide (II), in addition to the Boc protecting group on every amino acid, the side chains of some amino acids are further protected from reaction by the chemistry of peptide synthesis. In addition to those protecting groups described for the amino acids in the peptide (II) synthesis, the following protecting groups for the amino acids unique to peptides (III) and (IV) were used:

Hobt: 1-hydroxybenzotriazole; used in equimolar amounts to glutamine and asparagine during coupling to prevent dehydration to the nitrile forms.

Tosyl: p-toluene sulfonyl; used to acylate the guanidine group in the side chain of arginine.

Bzl: beta-benzyl ester; blocks the carboxyl groups in the side chain of aspartic acid and glutamic acid.

BrZ: 2-bromobenzyloxyarbonyl; blocks the hydroxyl group in the side chain of tyrosine.

Peptides were cleaved from the resin, filtered, extracted with acetic acid and run through a Fractogel desalting column as in Example 1. For peptide (IV), Fractogel fractions were analyzed by analytical HPLC and fractions containing at least 30% of the total absorption at 214 nm as the major peak migrating at approximately 14 minutes retention time were pooled. The pooled fractions were chromatographed on carboxymethyl cellulose equilibrated with 0.01 M ammonium acetate, pH 4.4. The column was eluted with a step gradient of ammonium acetate and the fraction eluting at 0.2M ammonium acetate was collected, lyophilized, and analyzed by analytical HPLC. The major peak migrating at 15 minutes retention time comprised between 30% and 40% of the total absorption at 214 nm and the material had an acceptable amino acid content. This material was

-49-

resolubilized and used in ELISA as described for peptide (II).

For peptide (III), Fractogel fractions were likewise analyzed by analytical HPLC. Fractions containing at least 70% of the total absorption at 214 nm as the major peak migrating at approximately 12.99 minutes retention time were pooled, lyophilized, and analyzed by HPLC and for amino acid content. This material was resolubilized and used in ELISA as described for peptide (II).

When used in combination as the solid phase component in an ELISA, 1 microgram of peptide (III) and 0.5 micrograms of peptide (IV) were used per microtiter well. The peptide was either dried onto the well at 37°C or "wet packed" onto the plate by incubation overnight at 4°C.

C. For peptide (V), Boc-serine resin was used as described for synthesis of peptide (III). Synthesis of (V) proceeded as described for synthesis of (III) through the addition of the C-terminal isoleucine of peptide (III). From that point on, for completion of the (V) sequence, the procedure for addition of the amino acids in the sequence AVERYLKDQQLLG in peptide (IV) was followed.

Peptide (V) was cleaved from the resin, filtered, extracted with acetic acid and run through a Fractogel fractions containing the major peak of absorption at 280 nm were pooled and labeled Fr:1. Fr:1 was analyzed for amino acid content and found to be acceptable. This fraction was lyophilized and used in ELISA as described for peptide (II).

D. Following similar procedures the peptides of formulas (I), (VI) through (XVI) were prepared.

35

-50-

E. Peptides (I) through (III), (V), and (VII) through (X) contain two cysteines. Accordingly, these peptides can polymerize and cyclize through oxidative disulfide bonding using atmospheric oxygen as the oxidant. The addition of the four amino acid residues at the C-terminal end of (III) apparently assist the cyclic form of the peptide in binding to the plastic in the ELISA assay. As a result, the cyclic form of (III) is more effective in solid phase ELISA than is (II) cyclic. The forms of the (II), (III) and (V) peptides used thus far in ELISA to assay for HIV-1 antibody recognition have been typically a mixture of linear monomer, cyclic monomer, dimer and polymer.

Peptides (IV), (VI) and (XI) contain only one cysteine. These peptides can form a dimer structure through disulfide bonding.

Under conditions of solubilization of peptides in preparation for ELISA (e.g., 0.1 M sodium bicarbonate buffer at pH 9.0 in the presence of air and its oxygen) most of the sulfhydryl groups of peptides (II), (III), (IV), and (V) have been converted to the disulfide form.

3. Preparation of Comparative HTLV-III Peptides

Following similar procedures to those of Examples 2 and 3, for comparative purposes, peptides having the following formulae were synthesized:

<u>SEQUENCE</u>	<u>DESIGNATION</u>
QLQARILAVERY	(C-I)
AVERYLKDQQLLG	(C-II),
LKDQQLLGIWGCS	(C-III),
IWGCSGKLI	(C-IV), and
LICTTAVPWNASWSN	(C-VIII).

-51-

These peptides each have sequences corresponding to the sequence of the HIV-1 envelope but are neither the di-cys nor di-leu polypeptides described previously. Specifically, peptides having the formula (C-I) and (C-II) are sequences upstream from the amino end of the sequence of formula (I) i.e., CSGLKIC. Peptides having the formula (C-III) contain only the amino terminal portion of the sequence of formula (I). Peptides having the formula (C-IV) contain the full sequence of formula (I), but for the carboxy-terminal L-cys residue. As will be described herein, each of these peptides fails to exhibit the desirable immunoreactive properties.

4. Preparation of HIV-1 ELISA Assay Kit and Procedure for Use:

A. Procedure #1 for HIV-1 ELISA

- (1) coat ELISA plate with peptide - 1ug/50ul/well in 0.1M NaHCO₃, pH 9;
- (2) let plates dry overnight uncovered at 37°C; then wash with PBS;
- (3) block plates with 300ul/well of blocking buffer (5% NCS-PBS) for 2 hrs. at 37°C;
- (4) shake out blocking buffer and drain well;
- (5) add 50ul/well test antiserum (first antibody) for 30 to 120 minutes at 37°C. (If the antiserum is to be diluted, use T-wash.) Dilutions of 1:2 to 1:100 have been used;
- (6) shake out test antisera and wash plate six times with PBS-Tween20;
- (7) add 100ul/well of labeled specific binding agent in the form of a enzyme-labeled second antibody diluted 1:4000 with T-wash. Maintain 30 to 120 minutes at 37°C;
- (8) shake out any unreacted second antibody and wash

-52-

plate six times with PBS-Tween20;

- (9) add 100ul/well OPD substrate (or 5ul ABTS solution) for 20 minutes at RT;
- (10) add 50ul/well of 4N H₂SO₄ to stop OPD reaction (or 100ul/well of 1% SDS for ABTS reaction);
- (11) read plate on an MR 500 Microplate ELISA plate reader. (490nm for OPD or 405 nm for ABTS).

Reagents:

- (1) 0.1M NaHCO₃ pH9;
- (2) NCS-PBS: phosphate buffered saline (PBS) containing 5% normal calf serum;
- (3) T-wash: (780ml TBS + 20ml NCS + 1.6g bovine serum albumin (BSA) + 0.4ml polyoxyethylene (20) sorbitan monolaurate (Tween20);
- TBS: 12.11g Tris Base
- 17.5g NaCl
- 1800ml H₂O
- pH to 7.6 with HCl (CA.3N)
- final volume at 2000 ml.
- (4) Washing buffer PBS-Tween20: 0.5ml Tween 20 per liter PBS;
- (5) OPD substrate: one o-phenylenediamine (OPD) tablet/3ml H₂O/1.24ul 30% H₂O₂;
- (6) 4N H₂SO₄;
- (7) ABTS: H₂O₂ in 1:1 ratio by volume of solutions supplied by Kirkegaard and Perry Laboratories, Inc., Gaithersbury, MD)
- ABTS = 2,2'-azino-di-[3-ethyl-benzthiazoline sulfonate];
- (8) 1% SDS: 1% sodium dodecyl sulfate.

The material used in step 1 for coating the ELISA plate is a peptide of formula (II), (III), (IV), (V) or a mixture thereof as described above. The second antibody is either a commercially-available

-53-

peroxidase-labeled, polyclonal anti-human immunoglobulin antibody (Cappel Laboratories Catalog No. 3201-0231; Peroxidase-conjugated IgG fraction of goat anti-human immunoglobulins) or a peroxidase-labeled mouse monoclonal anti-human IgG antibody (Ortho Diagnostics, Inc., Raritan, NJ), or a mixture of peroxidase-labeled mouse monoclonal anti-human IgG, IgA and IgM antibodies.

B. Procedure #2 for HIV-1 ELISA
(Tables 10 and 13):

- (1) Coat ELISA plate with peptides - 1.0 ug peptide IV, 0.5ug peptide III 200ul/well in 0.1M carbonate buffer, pH 9.6;
- (2) incubate plates overnight at 4°C;
- (3) block plates with 300ul/well 1.0% BSA-PBS plus additives for 1.5 hr at 37°C;
- (4) shake out blocking buffer;
- (5) dry plates for 1.0 hr at 37°C;
- (6) add 200ul/well 1% bovine gamma globulin - 5% BSA-0.5% Tween 20-PBS, pH 7.2;
- (7) add 20ul/well test sera, incubate 30 min at 37°C;
- (8) shake out test sera, wash plate 5x with PBS-0.5% Tween 20.
- (9) add 200ul/well horseradish peroxidase labeled monoclonal anti-human IgG diluted 1:3500 with 50% fetal calf serum-1% horse serum-0.5% Tween-PBS;
- (10) incubate 30 min at 37°C;
- (11) shake out labeled monoclonal anti-human IgG, wash plate 5x with PBS-0.05% Tween 20;
- (12) add 200ul/well OPD substrate and incubate for 30 min at room temperature;
- (13) add 50ul/well 4N H₂SO₄ to stop reaction;
- (14) Read plate at 490 nm in MR 500 Microplate Reader.

Reagents:

- (1) Phosphate Buffered Saline (PBS) pH 7.3;

- 8.0 g of sodium chloride;
0.2 g of potassium phosphate, monobasic;
1.16 g of sodium phosphate, dibasic;
0.2 g of potassium chloride;
5 0.2 g of thimerosal;
water to 800 ml and mix, adjust pH if
necessary;
add water to 1L.
- (2) Coating Buffer: pH 9.6, 0.01M carbonate
10 buffer.
- (3) Blocking buffer is PBS containing the
following additives:
1% bovine serum albumin (Sigma #A7030);
10 Ku/ml Aprotinin;
15 10ug/ml trypsin inhibitor;
10mM EACA (E-amino caproic acid);
0.5mM PMSF (phenyl-methyl-sulfonyl
fluoride);
2.0mM EDTA;
20 10% glycerol;
- (4) Specimen Diluent:
10.0g Bovine Gamma Globulin, Fraction II,
lyophilized;
50.0g Bovine Albumin, Fraction V;
25 0.5ml Polysorbate 20 (Tween20);
Add water to 1L and mix;
Filter through 0.2 micron filter.
- (5) Conjugate Diluent:
490ml PBS;
30 500ml heat inactivated fetal bovine serum;
10ml heat inactivated horse serum;
0.1g thimerosal;
0.329g potassium ferricyanide;
add water to 1L mix;
35 filter through 0.2 micron filter.

-55-

5. Evaluation of HIV-1 Peptide II Based ELISA

The ELISA kits described in Example 4A made with peptide (II) were evaluated against a panel of sera comprising sera from normal subjects, patients with disorders or diseases unrelated to AIDS, known AIDS patients, known ARC patients, and patients whose diagnosis is unknown but who are antibody-positive for HIV-2 antibodies by commercial tests or by Western blot assay. The results are summarized in Tables 4-7. For comparison, these same sera samples were assayed with commercially available kits that utilize a viral lysate as antigen and by Western blot assay. The commercial kits selected for these studies were from Abbott Laboratories, North Chicago, Ill. and Electro-Nucleonics, Inc. (ENI), Columbia, MD, and the directions supplied with each commercial kit were followed in carrying out each assay conducted in Tables 4-7. The assay using polypeptide (II) as the solid phase antigen and the procedure described in Example 4A is referred to as the "E8" assay in those Tables. Sera that exhibited similar results in the assays performed are grouped together in the following tables to clarify the presentation of the data.

A. Table 4 shows results with normal sera.

TABLE 4

<u>Assay of Normal Sera by ELISA Using Peptide (II)</u>					
# of	E8	ENI	Abbott	Diagnosis;	
<u>Samples</u>	<u>Assay</u>	<u>Assay</u>	<u>Assay</u>	<u>Sample ID</u>	
198	-	5-,194NT	41-,156NT	Normal	
1	-	-	+	Normal;749	
1	+	NT	NT	Normal;2846	
200					

-56-

Mean Absorbance of Normals=0.016 for E8 assay
Standard Deviation (S.D.) from the mean = 0.017
Absorbance Cutoff Value at Mean + S.D. = 0.104
False Positive rate in 200 samples at 0.104 cutoff =
5 0.5% (1/200)
NT = Not Tested
Sample ID = Serum Sample Number

10 As is shown in Table 4, subject sera
not containing antibodies to HIV-1 generally do not
react to peptide (II) in a standard ELISA. This
permits calculation of an absorption cutoff value to
distinguish between antibody-negative and antibody-
positive sera. In the above assay of 200 normal sera,
15 a cutoff value of 0.104 was selected. At this cutoff
value the false positive rate is expected to be less
than or equal to 0.5%.

B. To indicate the superior
effectiveness for eliminating false positives by
20 employing the peptide of formula (II) over the
commercially available kits using viral lysate as
target antigen, a number of sera from patients with
two disorders unrelated to AIDS, namely naso-
pharyngeal carcinoma and rheumatoid arthritis (RA),
25 were tested by the E8 assay and commercial tests. The
results are summarized in Table 5 below and indicate
the increased specificity of the E8 assay. Many
samples which gave false positive results with
commercial tests were correctly identified as negative
30 by the E8 assay.

-57-

TABLE 5
Test of Naso-Pharyngeal Carcinoma and
Rheumatoid Arthritis Patients

5	# of	E8	ENI	Abbott	Diagnosis;
	<u>Samples</u>	<u>Assay</u>	<u>Assay</u>	<u>Assay</u>	<u>Sample I.D.</u>
	6	(+)	NT	(+)	NPC/NON-AIDS
	17	-	NT	(+)	NPC/NON-AIDS
	8	-	NT	-	NPC/NON-AIDS
10	1	-	NT	NT	NPC/NON-AIDS
	1	-	(+)	-	RA/NON-AIDS; 920
	7	-	2-, 5NT	3-, 4NT	RA/NON-AIDS
	1	-	-	(+)	RA/NON-AIDS; 615

15 (+)=False Positives
 NT=Not Tested
 NPC=Naso-Pharyngeal Carcinoma
 RA=Rheumatoid Arthritis

20 C. To indicate the effectiveness of
 the E8 assay for detection of HIV-1 antibodies in
 AIDS/ARC patient sera compared to commercial kits, the
 ELISA kit described in Example 4-Procedure A was
 evaluated against a panel of sera derived from
 25 diagnosed AIDS and ARC patients. The results are
 summarized in Table 6 and show that the assay is
 equivalent to commercial kits for its ability to
 identify sera containing antibody to HIV-1.

30

35

-58-

TABLE 6

Assay of AIDS/ARC sera:

	# of	E8	ENI	Abbot	Diagnosis;
	<u>Samples</u>	<u>Assay</u>	<u>Assay</u>	<u>Assay</u>	<u>Sample I.D.</u>
5	67	+	+	+(16NT)	AIDS
	2	(-)	(-)	(-)	AIDS;533,3621
	1	(-)	+	+	AIDS;653
	2	+	+	(-)	AIDS;661,662
	21	+	+	+	ARC
10	<u>2</u>	(-)	(-)	(-)	ARC;512,529
	95				

 (-) = False Negatives

ARC = Aids Related Complex

15 NT = Not Tested

20 D. The high rate of false positives characteristic of presently available kits using viral lysate as antigen is due in part to the presence of cellular antigens in the lysate that react with antibodies present in both AIDS and non-AIDS patient sera. Additionally, complex antigens such as those derived from a virus such as HIV-1 contain many epitopes and are more likely to react non-specifically with antibodies present in human sera.

25 The peptide (II) reduces the complexity of the antigen used to react with patient sera down to one or perhaps only a few epitopes. The chance of non-specific interaction with non-HIV-1 antibodies is therefore greatly reduced. Non-specific interactions, however, may still occur since some antibodies are "sticky" and can bind to the plastic support used in the assay, or to other proteins such as bovine serum albumin or goat sera used to block the plate after addition of the peptide.

-59-

Presented in Table 7 below are data relating to the assay of various patient sera. In addition to the usual assay with peptide (II) as described in Example 4-Procedure A, each serum was assayed against peptide (II) after mixing the serum sample with an effective blocking amount of the peptide (II). Also included in the Table are the results of assaying each sample with commercially available kits.

It is evident from these results that non-AIDS sera samples incorrectly identified as positive by either or both of the commercially available kits are correctly identified as negative using the E8 peptide competition assay. Furthermore, even samples incorrectly identified as positive by the E8 assay are correctly identified as negative by the E8 peptide competition assay. Significantly, the blocking or competition assay also serves as a confirmatory assay in assays of serum samples that do contain antibodies to HIV-1. The last seven samples assayed as shown in Table 7 are positive for antibody by both the E8 assay and commercially available assays (with the exception of two false negatives using the Abbott kit) and by the more tedious and time consuming Western blot assay. The reactivity of these sera with peptide (II) as solid phase antigen is effectively blocked by mixing each serum with peptide (II), indicating that the reactivity of antibody to peptide is peptide-specific, and that these last seven samples are true positives.

-60-

TABLE 7

Competition Assay Confirming Positive/Negative ELISA:

5	ELISA Value		Abbott Assay	ENI Assay	Western Assay	Diagnosis
	Samp. I.D.	Score with Peptide Not Blocked Blocked (Score)				
10	615	0.031	0.033(-)	-	-	RA
	3195	0.026	0.045(-)	-	+	DP
	3196	0.028	0.039(-)	-	+	DP
	3197	0.065	0.073(-)	-	+	DP
	3376	0.104	0.105(-)	-	+	UNK
	3362	0.740	0.727(-)	-	+	UNK
15	912	0.055	0.065(-)	+	NT	NPC
	918	0.100	0.092(-)	+	NT	NPC
	922	0.127	0.103(-)	+	NT	NPC
	923	0.114	0.080(-)	+	NT	NPC
20	3644	0.336	0.380(-)	+	+	UNK
	3406	1.400	1.390(-)	+	+	DP
	3461	1.426	1.137(-)	+	+	DP
25	3532	1.770	0.080(+)	+	+	UNK
	3469	0.300	0.030(+)	+	+	UNK
	3431	0.507	0.087(+)	NT	+	UNK
	644	0.160	0.024(+)	NT	+	AIDS
	659	0.510	0.042(+)	+	+	AIDS
	661	0.500	0.031(+)	-**	+	AIDS
	662	0.160	0.030(+)	-**	+	AIDS

-61-

* = False Positive
** = False Negative
DP = Dialysis Patient, Non-Aids
5 NPC= Naso-Pharyngeal Carcinoma, Non-Aids
UNK=Unknown
RA= Rheumatoid Arthritis, Non-Aids
(-) and - = HIV-1 Antibody Negative
(=) and + = HIV-1 Antibody Positive

10

6. Comparison of HIV-1 Peptides (I)-(XV)
and (C-I) - (C-III) by ELISA

Elisa kits as described in Example 4-

15 Procedure A were made with peptides (I) through (XV)
as well as (C-I) through (C-VIII). The ELISA kits
were each evaluated against a ten sample panel of sera
comprising clinically positive samples, i.e., samples
that evidenced the presence of HIV-1 infection as
determined by commercial assays and Western blot
20 assay. The results of these assays are shown in Table
8 below.

A peptide assay is considered positive if
the absorbance (optical density) level of the ELISA
assay was more than twice the background level as
25 determined by averaging the absorbance of two normal
sera. The mean value reported represents the mean
optical density value of the ELISA as calculated after
the background value was subtracted. The index
reported is a weighted activity of a given peptide
30 relative to the activity of the peptide of formula
(II). The index is weighted in favor of the ability
of a particular peptide assay to correctly report a
positive value as distinguished from the level of the
background normal response. The formula for deriving
35 the index is as follows:

-62-

$$\frac{(\% \text{ Positive})^3 \times \text{MEAN}}{(\% \text{ Positive}_{\text{II}})^3 \times \text{MEAN}_{\text{II}}} = \text{Index}$$

5

wherein: % Positive is % Positive for the given peptide assay;

MEAN is MEAN for the given peptide assay;

% Positive_{II} is % Positive for peptide assay

10 having the formula (II); and

% MEAN_{II} is MEAN for the peptide assay

having the formula (II).

As can be seen from Table 8, assays made
 15 using peptides having the formulas (I) through (V),
 all provide positive results of at least 50% or
 greater and in each case manifest an index of at least
 0.1. On the other hand, each of the comparative
 segments, although representing closely adjacent or
 20 overlapping or partially overlapping segments from the
 HIV-1 envelope, fail to exhibit such positive results
 or such high index. These data also show that use of
 a mixture of polypeptides (III) and (IV) provides an
 improved result as to mean and index values than does
 25 polypeptide (V) whose sequence contains the
 combination of the sequences of (III) and (IV).

30

35

-63-

TABLE 8

PEPTIDE		SEQUENCE	% POSITIVE	MEAN	INDEX
5	FORMULA				
	(II)	IWGCSGKLICTTAVP	80	1.67+0.82	1.00
	(C-V)	QLTVWGIKQLQARIL	0	-	0
	(C-VI)	GIKQLQARILAVERY	20	0.45+0.06	0.01
	(C-I)	QLQARILAVERY	0	-	0
	(C-IX)	QARILAVERYLKDQQ	0	-	0
10	(XV)	RILAVERYLKDQQLLGIWGCS	90	2.01+1.40	1.56
	(C-II)	AVERYLKDQQLLG	10	0.04 -	<0.01
	(C-VII)	AVERYLKDQQLLGIW	60	1.18+0.68	0.35
	(IV)	AVERYLKDQQLLGIWGCSGKLI	100	2.23+0.68	2.26
15	(XII)	AVERYLKDQQLLGIWGCSGKLI	100	1.95+0.27	2.11
	(C-III)	LKDQQLLGIWGCS	30	0.28+0.06	0.02
	(XIV)	LKDQQLLGIWGCSGK	90	1.69+0.65	1.43
	(VI)	LKDQQLLGIWGCSGKLI	100	1.19+0.85	1.65
	(VII)	LLGIWGCSGKLI	50	0.22+0.05	0.09
20	(XI)	LLGIWGCSGKLICTT	80	1.53+0.77	0.96
	(C-IV)	IWGCSGKLI	20	0.17+0.00	0.01
	(I)	CSGKLI	60	0.34+0.11	0.19
	(VIII)	QQLLGIWGCSGKLICTTAVPWNAS	90	0.51+0.25	0.79
	(IX)	IWGCSGKLICTTAVPWN	70	0.86+0.45	0.48
25	(III)	IWGCSGKLICTTAVPWNAS	100	2.20+0.86	2.24
	(XIII)	GCSGKLICTTAVPWN	100	2.14+0.58	2.21
	(X)	CSGKLICTTAVPWNAS	100	1.74+1.01	1.99
	(XI)	SGKLICTTAVPWNAS	50	0.86+0.63	0.17
	(C-VIII)	LICTTAVPWNASWSN	0	-	0
30	(V)	AVERYLKDQQLLGIWGCSGKLICTTAVPWNAS	100	1.53+0.66	1.89
	(III)	AVERYLKDQQLLGIWGCSGKLI +			
	(IV)	IWGCSGKLICTTAVPWNAS	100	>3.0 -	2.62

-64-

7. Comparison of ELISAs Using HIV-1
Peptides (III) and (IV)

Additional AIDS/ARC patient sera were
 assayed with ELISA assays employing the two highly
 5 reactive peptides of formulas (III) and (IV) (Example
 IV-Procedure 1). The reactivity, expressed as
 absorbance values, of some of these sera is shown in
 Table 9.

10

TABLE 9.

		<u>PEPTIDE FORMULA</u>	
	<u>SERUM SAMPLE</u>	<u>(III)</u>	<u>(IV)</u>
	3362	0.503	0.151
	3412	>2.00	0.540
15	A. 3693	0.559	0.120
	3722	0.620	0.193
	0649	1.756	0.379

	3555	0.428	>2.00
20	3575	0.350	1.773
	3744	0.311	1.326
	B. 3790	0.224	1.765
	0509	0.403	2.000
	0653	0.111	0.999
25	0662	0.301	1.392

	3416	1.914	>2.00
	3456	1.670	1.780
	C. 3666	>2.00	>2.00
30	3414	1.453	1.057
	3411	>2.00	>2.00
	3413	>2.00	>2.00

35

-65-

Most sera assayed reacted very well with both peptides, much as is seen with samples in Table 9, group C. Occasionally, however, some samples were far more reactive with one peptide than the other, as shown in Table 9, groups A and B. These data indicate that there may be more than one epitope (e.g., a linear and a conformational epitope or two linear epitopes) in this thirty-two amino acid region that is commonly recognized by patients that have been exposed to HIV-1. High performance liquid chromatography (HPLC) analysis of peptides of formulas (III) and (IV) in solution indicate that formula (III) peptides exist largely as cyclic monomers, while formula (IV) peptides are mostly in dimer form. The structural characteristics imparted to these two peptides by disulfide bonding may be related to both antigen presentation and the creation of a conformation epitope.

The differential reactivity of polypeptides (III) and (IV) was further examined by comparing the absorbance values obtained for each peptide in ELISAs performed according to Example 4B using peptide (III), peptide (IV) or a combination of (III) and (IV) as solid phase antigen. The absorbance values obtained for each of 37 sera in the peptide (III) based ELISA were divided by those obtained in the peptide (IV) based ELISA. The resulting absorbance value ratios are shown in ranked order in Table 10.

From Table 10 it can be seen that 30 out of the 37 sera examined demonstrated a greater immunoreactivity for peptide (III) than peptide (IV).

-66-

TABLE 10
Comparison of Polypeptides (III) and (IV)

	Serum No.	Ratio			
		(III)	(IV)	(III):(IV)	(III)+(IV)
5	4099	2.000	0.018	111.11	2.000
	4074	0.980	0.019	51.58	1.260
	4084	2.000	0.039	51.28	1.834
	0641	0.641	0.014	45.79	0.834
	4109	2.000	0.088	22.73	2.000
10	4100	2.000	0.105	19.05	1.930
	3228	1.682	0.125	13.46	1.538
	3868	0.200	0.022	9.09	0.572
	4062	0.187	0.022	8.50	0.422
	4089	0.756	0.108	7.00	1.130
15	3869	0.548	0.134	4.09	1.019
	4008	0.664	0.215	3.09	1.246
	4067	1.806	0.644	2.80	1.780
	4068	1.773	0.649	2.73	1.898
	4007	1.866	0.776	2.40	1.730
20	4086	1.503	0.644	2.33	1.473
	3980	0.280	0.131	2.14	0.560
	4082	1.518	0.786	1.93	1.781
	3544	0.322	0.167	1.93	0.385
	4006	0.214	0.120	1.78	0.340
25	4071	0.810	0.504	1.61	1.164
	4117	2.000	1.262	1.58	1.955
	4078	2.000	1.318	1.52	2.000
	4095	2.000	1.396	1.43	2.000
	3281	0.804	0.569	1.41	1.544
30	4111	2.000	1.587	1.26	2.000
	4092	0.552	0.462	1.19	1.764
	4010	2.000	1.832	1.09	2.000
	4063	0.642	0.597	1.08	0.848
	3226	2.000	1.897	1.05	2.000
35	4083	2.000	2.000	1.00	2.000

-67-

TABLE 10 continued...

Serum No.	Ratio			
	(III)	(IV)	(III):(IV)	(III)+(IV)
4110	1.964	2.000	0.98	2.000
5 3455	0.239	0.244	0.98	0.196
3785	0.170	0.352	0.48	0.493
4077	0.400	1.040	0.38	1.290
4115	0.042	0.150	0.28	0.271
3983	0.070	1.767	0.04	1.988

8. HIV-1 Peptide Competitive Inhibition Studies

Further evidence that more than one epitope is present in formula (III) and (IV) peptides can be deduced from absorbance values obtained from competition studies, the results of an example of which are shown in Table 11. In this study, admixed formula (III) and (IV) peptides were applied to a microtiter plate as the immobilized, solid phase antigen and an ELISA assay (Example 4A) was performed under five different conditions: without competition, or competition with excess formula (III) peptide, formula (IV) peptide, an admixture of both peptides [(III)+(IV)], or with a heterologous peptide. The competition was performed by adding the appropriate peptide(s) to the diluted serum just before adding the serum sample to the microtiter well.

-68-

TABLE 11

COMPETING PEPTIDE FORMULA

	UN-					
	<u>SAMPLE</u>	<u>BLOCKED</u>	<u>(III)</u>	<u>(IV)</u>	<u>(III)+(IV)</u>	<u>HETEROLOGOUS</u>
5	3412	1.450	0.113	1.182	0.059	1.348
	3413	>2.00	0.381	2.032	0.068	2.026
	3416	>2.00	1.811	1.055	0.197	2.041
	3544	1.810	0.876	0.137	0.048	1.750
	3575	1.267	0.982	0.105	0.036	1.304
10	3693	0.340	0.103	0.217	0.065	0.293
	3790	1.558	1.320	0.635	0.134	1.349

Under these conditions it is very clear that some samples react very well with each or both of peptides (III) and (IV). For example, sample 3416 reacted well with an admixture of both peptides, since competition with the formula (III) peptide alone gave an optical density (OD) of >1.8, competition with the formula IV peptide yielded an OD of 1.055 and, in the presence of both competing peptides, the OD went down essentially to background levels. Other serum samples such as 3412 reacted much more strongly with one peptide than the other; in this case, the OD was reduced from >1.4 down to 0.113 when blocked with formula (III) peptide, and remained >1 when competed with formula (IV) peptide. However, there is clearly some reactivity with formula (IV) peptide because, in the presence of both peptides, immunoreactivity is completely abolished (0.059). Still further, admixture of peptides (III) and (IV) as competing peptides always provided a better result than did the use of either peptide alone.

Another competition study with the formula (I) peptide on the plate as solid phase antigen and

-69-

using the procedure of Example 4A, showed that formula (IV) peptide did not effectively compete with formula (I) peptide although the formula (III) peptide competed very effectively. See Table 12 below.

5

TABLE 12

COMPETING PEPTIDE FORMULA

UN-					
<u>SAMPLE</u>	<u>BLOCKED</u>	<u>(I)</u>	<u>(III)</u>	<u>(IV)</u>	<u>HETEROLOGOUS</u>
10 013	1.177	0.038	0.046	0.770	0.865
014	0.383	0.050	0.067	0.273	0.324

Thus, it appears from these analysis that an epitope present in formula (III) peptide is also present on formula (I) peptide, and that this epitope is substantially different from those present in formula (IV) peptide. Furthermore, based on this same sample, virtually all sera reacted with the epitopes presented on the formula (III) and (IV) peptides, although in many cases, more strongly with one peptide than with the other.

9. ELISA Using a Combination of HIV-1 Peptides (III) and (IV)

Using a combination of one microgram of formula (III) and 0.5ug of formula (IV) peptides per well as the solid phase antigen in an ELISA assay (Example 4B), the specificity and sensitivity of this assay was equal or superior to any of the commercially available viral lysate antibody detection kits tested.

Table 13 presents ELISA results obtained using patient sera, normal sera, and sera from miscellaneous disease groups that include rheumatoid arthritis, naso-pharyngeal carcinoma, Epstein-Barr virus infection, cytomegalovirus infection, gram

-70-

negative sepsis, toxoplasma gondii, systemic lupous erythematosus, and herpes virus infections.

TABLE 13

5

		NUMBER	ENI	(III) +(IV)	ENI	(III) +(IV)
	<u>SAMPLE GROUP</u>	<u>OF SERA</u>	<u>POS</u>	<u>POS</u>	<u>NEG</u>	<u>NEG</u>
10	AIDS + ARC	458(243)*	449	450	9	8
	SYMPTOMATIC PLS	320(146)	239	242	81	78
	ASYMPTOMATIC/HIGH RISK					
	IMMUNE ABNORMALITIES	135(87)	38	39	97	96
15	ASYMPTOMATIC/HIGH RISH					
	IMMUNE NORMAL	134(69)	10	10	124	124

	NORMAL/NON-AIDS	728(728)	12	4	716	724
20	MISCELLANEOUS DISEASE					
	GROUPS/NON-AIDS	387(387)	10	7	377	380

	TOTAL NON-AIDS	1115	22	11	1093	1104

* Numbers in parentheses indicate number of patients

When bona fide normal sera were assayed for reactivity in the (III)+(IV) assay and in the assay marketed by Electronucleonics, Incorporated (ENI), the (III)+(IV) peptide assay had a significantly lower false positive rate. As the data of Table 13 show, the false positive rate for ENI was 1.65% (12/728), whereas the (III)+(IV) peptide assay had a false positive rate of only 0.55% (4/728). When the false positive rate in the Miscellaneous Disease Group is examined, the peptide assay had a slightly lower false positive rate than did the ENI assay, 1.81% vs. 2.58% (7/387 vs. 10/387).

-71-

10. Synthesis of STLIV-III-related Polypeptides

Synthesis of polypeptides p80 and p81 was accomplished using substantially the same classical Merrifield technique as described earlier. For peptide p80, Boc-cysteine resin with substitution of 0.71 mMole/gram, prepared as in Example 2, was used. For peptide p81, Boc-serine resin with substitution of 0.67 mMole/gram, prepared as in Example 2, was used.

A. For polypeptide p80, the amino acid residue sequence AIEKYLEDDQAQLNAWCAFRQVC was synthesized using the following Boc-L-amino acids in twelve molar equivalents (meq) excess:

	<u>Amino Acid</u>	<u>Solvent</u>
15	Boc-Val	CH ₂ Cl ₂
	Boc-Gln/Hobt	DMF
	Boc-(Tosyl)-Arg	10% DMF/CH ₂ Cl ₂
	Boc-Phe	CH ₂ Cl
	Boc-Ala	CH ₂ Cl ₂
20	Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
	Boc-Trp	10% DMF/CH ₂ Cl ₂
	Boc-Ala	CH ₂ Cl ₂
	Boc-Asn/Hobt	DMF
	Boc-Leu	10% DMF/CH ₂ Cl ₂
25	Boc-Gln/Hobt	DMF
	Boc-Ala	CH ₂ Cl ₂
	Boc-Gln/Hobt	DMF
	Boc-(Bzl)-Asp	CH ₂ Cl ₂
	Boc-(Bxl)-Blu	CH ₂ Cl ₂
30	Boc-Leu	10% DMF/CH ₂ Cl ₂
	Boc-(Br-Z)-Typ	CH ₂ Cl ₂
	Boc-(Cl-Z)-Lys	CH ₂ Cl ₂
	Boc-(Bzl)-Glu	CH ₂ Cl ₂
	Boc-Ile	CH ₂ Cl ₂
35	Boc-Ala	CH ₂ Cl ₂

-72-

B. For polypeptide p81, the amino acid residue sequence AWCAFRQVCHTTVPWPNAS was synthesized using the following Boc-L-amino acids in twelve meq excess:

5		<u>Amino Acid</u>	<u>Solvent</u>
		Boc-Ala	CH ₂ Cl ₂
		Boc-Asn/Hobt	DMF
		Boc-Pro	CH ₂ Cl ₂
10		Boc-Trp	10% DMF/CH ₂ Cl ₂
		Boc-Pro	CH ₂ Cl ₂
		Boc-Val	CH ₂ Cl ₂
		Boc-(O-Bzl)-Thr	CH ₂ Cl ₂
		Boc-(O-Bzl)-Thr	CH ₂ Cl ₂
15		Boc-(Z-Carbobenzoxy)-His	CH ₂ Cl ₂
		Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
		Boc-Val	CH ₂ Cl ₂
		Boc-Gln/Hobt	DMF
		Boc-(Tosyl)-Arg	10% DMF/CH ₂ Cl ₂
20		Boc-Phe	CH ₂ Cl ₂
		Boc-Ala	CH ₂ Cl ₂
		Boc-(MeOBzl)-Cys	CH ₂ Cl ₂
		Boc-Trp	10% DMF/CH ₂ Cl ₂
		Boc-Ala	CH ₂ Cl ₂
25			

Polypeptides were individually cleaved from the respective resins, extracted with acetic acid, run through a Fractogel desalting column and were analyzed as in Example 1.

30 11. Evaluation of STLV-III Polypeptides P80 and P81, Alone and in Combination, by ELISA

Preliminary studies using two sera containing high titers of antibodies against HIV-2 were performed by ELISA using each of p80 and p81

35

-73-

alone and in combination. One hundred microliters (ul) of 0.01M NaHCO₃, pH 9.6, containing 1 microgram (ug) of either p80 or p81 or a combination (admixture) of 1 ug of p80 and 1 ug of p81 were admixed into the wells of Immunolon II microtiter plates (Dynatech, Alexandria, VA). The plates were then maintained for about 16 hours at 4 degrees C to permit the polypeptides to adsorb onto (coat) the walls of the wells. After removing the polypeptide coating solution by shaking, 300 ul of PBS containing 1% bovine serum albumin (BSA), 5mM benzamidine, 10 kilounits Aprotinin, 10ug/ml Trypsin Inhibitor, 10mM EACA, 0.5mM PMSF, 2mM EDTA and 10% glycerol were admixed into each well to block excess protein binding sites.

The wells were maintained 90 minutes at 37 degrees C, the blocking solution was removed by shaking, and the wells were dried by maintaining them for 1 hour at 37 degrees C, thus forming a diagnostic system of the present invention, i.e., a STLV-III-related polypeptide-containing solid support (polypeptide-coated well).

Two hundred ul of each serum diluted 1:10 in TBS were admixed into a polypeptide-coated well. The resulting solid-liquid phase immunoreaction admixture was maintained at 37 degrees C for 30 minutes to permit formation of polypeptide-containing immunoreaction products. The wells were then rinsed 5 times with PBS containing 0.05% Tween20.

Two hundred ul of a horseradish peroxidase-labeled mouse monoclonal anti-human IgG antibody (Ortho Diagnostic Systems, Inc., Raritan, NJ), diluted 1:3500 in PBS containing 50% fetal calf serum, 1% horse serum and 0.5% Tween20, were then admixed into each well. The resulting labeling-reaction admixture

-74-

was maintained for 30 minutes at 37 degrees C to permit formation of polypeptide-containing labeled complexes. The wells were then rinsed 5 times with PBS-0.05% Tween20 to remove non-reacted labeled-
5 antibody.

Two hundred ul of OPD substrate were then admixed into each well to form a developing-reaction admixture. After maintaining the developing-reaction admixture for 30 minutes at about 20 degrees C, 50 ul
10 of 4N H₂SO₄ were admixed into each well to stop the developing-reaction, and the resulting solutions were assayed for absorbance at 490nm using a microtiter plate reader.

The results of the these studies indicated
15 that both p80 and p81 are capable of immunoreacting with antibodies induced by HIV-2. Polypeptide p80 produced absorbance values of greater than 1.1 with both sera, whereas p81 produced values of about 0.4. When the ELISAs were performed using an admixture of
20 p80 and p81, absorbance values comparable to those obtained with p81 alone were seen.

12. HIV-1 and STLV-III Polypeptide Specificity Studies

Three groups of sera were used to evaluate
25 the ability to the HIV-1 and STLV-III polypeptides to distinguish between antibodies induced by HIV-1 and HIV-2 infections. The first group consisted of 20 sera obtained from HIV-2 isolate antibody positive West African patients collected while they were
30 attending an outward clinic in Bissau, Guinea-Bissau, for examinations related to suspected tuberculosis. All of these sera immunoreacted with HIV-2 by ELISA using disrupted virions (viral lysate) as antigen. These sera also contained antibodies that reacted with
35 the TMP (gp36) of HIV-2 in a Western blot assay, but

-75-

demonstrated no reactivity with the TMP (gp41) of HIV-1.

The second group included sera from 20 HIV-1 antibody positive asymptomatic Swedish subjects (homosexual men, intravenous drug abusers or hemophiliacs) reacting in the Western blot assay with the TMP (gp41) and other antigens of HIV-1, but not with the TMP (gp36) of HIV-2.

The third group consisted of 20 sera from Swedish blood donors negative for HIV-1 and HIV-2 antibodies when assayed using commercially available diagnostic systems obtained from Organon, Teknika, N.V., Turnhout, Belgium, and Wellcome Reagents, Ltd., London, U.K. and the HTLV-IV viral lysate ELISA.

Solid supports comprising a combination of HIV-1 polypeptides (III) and (IV) affixed to microtiter plate wells were prepared as described in Example 11 using 200 μ l of 0.1M NaHCO_3 , pH 9.6, containing 5 μ g/ml of each polypeptide to coat the wells. Also prepared according to Example 11 were a different set of solid supports comprising STLV-III polypeptide p80 affixed to microtiter plate wells. All three groups of the above described sera were then assayed using both the (III)+(IV) polypeptide combination-containing (HIV-1 specific) and p80-containing (HIV-2 specific) solid supports according to the ELISA procedure of Example 11.

The ELISA results of all three groups of sera are illustrated in Figure 3. The 20 sera containing antibodies to HIV-2 but not to HIV-1 TMP gp41 gave pronounced reactions with STLV-III-related polypeptide p80 but, except for one serum, produced no substantial immunoreaction with the combination of HIV-1-related polypeptides (III) and (IV).

35

-76-

In contradistinction, the 20 sera with antibodies against HIV-1 reacted with the solid supports containing polypeptides (III) and (IV) but, again with one exception, produced no substantial immunoreaction with the solid supports containing only p80. The negative control sera did not produce any substantial immunoreaction with either the HIV-1- or STLV-III-specific solid supports.

From subsequent analysis of the two sera producing immunoreaction with both HIV-1- and STLV-III-specific solid supports it is believed that the individuals from whom those sera were obtained had been exposed to both the HIV-1 and HIV-2 viruses.

Because polypeptides (III) and (IV) were found to be differentially reactive, (Example 7), polypeptides p80 and p81 were similarly compared. The absorbance values obtained for each of 24 sera in a peptide p80 based ELISA were divided by those obtained in a peptide p81 based ELISA. The resulting absorbance value ratios are shown in ranked order in Table 14.

From Table 14 it can be seen that 19 out of the 24 sera examined demonstrated a greater immunoreactivity for p80 than for p81.

Thus, the present invention provides an assay system and method for distinguishing between exposure to HIV-1 versus exposure to HIV-2 as well as exposure to either.

-77-

TABLE 14
Comparison of Peptides p80 and p81

	Serum		Ratio	
	<u>No.</u>	<u>p80</u>	<u>p81</u>	<u>p80:p81</u>
5	6602	0.516	0.001	516.000
	6698	2.000	0.022	90.910
	5740	2.000	0.043	46.510
	6877	0.248	0.008	31.000
	6650	0.700	0.034	20.590
10	3616	0.686	0.047	14.600
	3942	0.588	0.051	11.530
	6674	2.000	0.258	7.752
	3541	0.181	0.025	7.240
	3743	0.257	0.040	6.425
15	6665	0.254	0.053	4.792
	6604	1.808	0.400	4.520
	6661	0.647	0.160	4.044
	6603	1.152	0.421	2.736
	3923	0.180	0.067	2.687
20	6601	0.353	0.138	2.558
	5182	0.162	0.102	1.588
	6600	0.359	0.306	1.173
	5160	0.251	0.236	1.064
	5727	0.504	0.563	0.895
25	6599	0.206	0.232	0.888
	6683	0.387	0.489	0.791
	6631	0.153	0.285	0.537
	6598	0.072	0.205	0.351

30 The foregoing specification, including the
specific embodiments and examples, is intended to be
illustrative of the present invention and is not to be
taken as limiting. Numerous other variations and
modifications can be effected without departure from
35 the true spirit and scope of the present invention.

-78-

What Is Claimed Is:

1. A polypeptide consisting essentially of no more than about 50 amino acid residues and including an amino acid residue sequence that has the sequence represented by the formula:

-CAFRQVC-,

said polypeptide being capable of immunoreacting with antibodies induced by HIV-2.

2. The polypeptide according to claim 1 wherein said polypeptide does not substantially immunoreact with antibodies induced by HIV-1.

3. The polypeptide according to claim 1 containing no more than 33 amino acid residues and wherein the amino acid residue sequence of said polypeptide is homologous to a portion of the sequence shown in Figure 1.

4. The polypeptide according to claim 3 wherein said polypeptide has an amino acid residue sequence represented by a formula selected from the group consisting of:

AIEKYLEDDQAQLNAWCAFRQVC,

AWCAFRQVCHTTVPWPNAS,

AIEKYLEDDQAQLNAWGCAFRQVC,

AVEKYLKDQAQLNAWGCAFRQVC,

AIEKYLKDQAQLNSWGCAFRQVC,

SWGCAFRQVCHTSVPWVNDT,

AWGCAFRQVCHTTVPWPNAS,

AWGCAFRQVCHITVPWPNAS, and

CAFRQVC.

5. A polypeptide consisting essentially of no more than about 50 amino acid residues and including an amino acid residue sequence that is represented by the formula:

-AWGCAFRQVC-

- said polypeptide being capable of immunoreacting with

antibodies induced by HIV-2.

6. A polypeptide consisting essentially of no more than about 50 amino acid residues and including an amino acid residue sequence represented by a formula selected from the group consisting of:

5 -AIEKYLEDDQAQLNAWCAFRQVC-,
 -AWCAFRQVCHTTVPWPNAS-,
 -AIEKYLEDDQAQLNAWGCAFRQVC-,
 -AVEKYLKDQAQLNAWGCAFRQVC-,
10 -AIEKYLKDQAQLNSWGCAFRQVC-,
 -SWGCAFRQVCHTSVPWVNDT-,
 -AWGCAFRQVCHTTVPWPNAS-,
 -AWGCAFRQVCHITVPWPNAS-, and
 -CAFRQVC-.

15 7. A method of assaying for the presence of anti-HIV-2 antibodies in a body fluid sample comprising the steps of:

 (a) forming an immunoreaction admixture by admixing a body fluid sample with a
20 polypeptide consisting essentially of no more than about 50 amino acid residues and including an amino acid residue sequence represented by the formula:

 -CAFRQVC-,

25 said polypeptide being capable of immunoreacting with antibodies induced by HIV-2;

 (b) maintaining said immunoreaction admixture under biological assay conditions for a time period sufficient for any anti-HIV-2 antibodies present in the sample to immunoreact with said
30 polypeptide and form a polypeptide-containing immunoreaction product; and

 (c) assaying for the presence of any polypeptide-containing immunoreaction product that formed, and thereby the presence of any anti-HIV-2
35 antibodies in said sample.

-80-

8. The method according to claim 7 wherein said polypeptide has an amino acid residue sequence represented a formula selected from the group consisting of:

5 AIEKYLEDDQAQLNAWCAFRQVC,
AWCAFRQVCHTTVPWPNAS,
AIEKYLEDDQAQLNAWGCAFRQVC,
AVEKYLKDQAQLNAWGCAFRQVC,
AIEKYLKDQAQLNSWGCAFRQVC,
10 SWGCAFRQVCHTSVPWVNT,
AWGCAFRQVCHTTVPWPNAS,
AWGCAFRQVCHITVPWPNAS, and
CAFRQVC.

9. The method according to claim 7 wherein
15 said polypeptide-containing immunoreaction product is further prepared for assaying according to step (c) by:

(i) forming a labeling reaction
admixture by admixing with said polypeptide-containing
20 immunoreaction product labeled specific binding agent capable of binding to any human immunoglobulin product, and

(ii) maintaining said labeling
reaction admixture so formed under biological assay
25 conditions for a time period sufficient for said labeled antibodies to immunoreact with any anti-HIV-2 antibodies present as polypeptide-containing immunoreaction product to form a labeled complex.

10. The method according to claim 9 wherein
30 prior to said admixture of step (a) said polypeptide is affixed to a solid matrix.

11. A diagnostic system in kit form for
assaying for the presence of anti-HIV-2 antibodies in
a body fluid sample comprising a package containing a
35 polypeptide consisting essentially of no more than

-81-

about 50 amino acid residues and including an amino acid residue sequence represented by the formula:

-CAFRQVC-,

5 said polypeptide being capable of immunoreacting with antibodies induced by HIV-2.

12. The diagnostic system according to claim 11 wherein said polypeptide has an amino acid residue sequence represented by a formula selected from the group consisting of:

10 AIEKYLEDDQAQLNAWCAFRQVC,
AWCAFRQVCHTTVPWPNAS,
AIEKYLEDDQAQLNAWGCAFRQVC,
AVEKYLKDQAQLNAWGCAFRQVC,
AIEKYLKDQAQLNSWGCAFRQVC,
15 SWGCAFRQVCHTSVPWVNDT,
AWGCAFRQVCHTTVPWPNAS,
AWGCAFRQVCHITVPWPNAS, and
CAFRQVC.

13. The diagnostic system according to claim 11 further including a HIV-1-related di-cys polypeptide consisting essentially of no more than 50 amino acid residues and including an amino acid residue sequence represented by the formula:

-CSGKLIC-,

25 said HIV-1-related polypeptide being capable of immunoreacting with antibodies induced by HIV-1.

14. The diagnostic system according to claim 13 wherein said HIV-1-related di-cys polypeptide has an amino acid residue sequence represented by a formula selected from the group consisting of:

30 CSGKLIC,
IWGCSGKLICTTAVP,
IWGCSGKLICTTAVPWNAS,
AVERYLKDQQLLGIWCSGKLICTTAVPWNAS,
35 LLGIWCSGKLIC,

-82-

QQLLGIWGCSGKLICTTAVPWNAS,
IWGCSGKLICTTAVPWN,
CSGKLICTTAVPWNAS,
AVERYLKDQQLLGIWGCSGKLI, and
GCSGKLICTTAVPWN.

- 5
15
10 15. The diagnostic system according to claim 11 further including a HIV-1-related di-leu polypeptide consisting essentially of no more than 50 amino acid residues and including an amino acid residue sequence represented by the formula:

-ZLLG(X)WZ-,

wherein X is selected from the group consisting of I, L, M or F;

- 15
15 wherein Z is selected from the amino acid residue sequence of the HIV-1 virus gp41 protein immediately adjacent to the amino side of the L-leucine residue in the 599th position of said gp41 protein;

- 20
20 wherein Z' is selected from the amino acid residue sequence of the HIV-1 virus gp41 protein immediately adjacent to the carboxy side of the L-tryptophan residue in the 603rd position of said gp41 protein; and

- 25
25 wherein one of Z or Z' may be zero residues long and wherein Z and Z' together comprise at least ten residues.

- 30
30 16. The diagnostic system according to claim 15 wherein said HIV-1-related di-leu polypeptide has an amino acid residue sequence represented by a formula selected from the group consisting of:

IWGCSGKLICTTAVPWNAS,
LKDQQLLGIWGCSGLKI,
LKDQQLLGIWGCSGK,
RILAVERYLKDQQLLGIWGCS, and
AVERYLKDQQLLGIWGCSGLI.

35

-83-

17. The diagnostic system according to claim 13 further including a HIV-1-related di-leu polypeptide consisting essentially of no more than 50 amino acid residues and including an amino acid residue sequence represented by the formula:

-ZLLG(X)WZ-,

wherein X is selected from the group consisting of I, L, M or F;

wherein Z is selected from the amino acid residue sequence of the HIV-1 virus gp41 protein immediately adjacent to the amino side of the L-leucine residue in the 599th position of said gp41 protein;

wherein Z' is selected from the amino acid residue sequence of the HIV-1 virus gp41 protein immediately adjacent to the carboxy side of the L-tryptophan residue in the 603rd position of said gp41 protein; and

wherein one of Z or Z' may be zero residues long and wherein Z and Z' together comprise at least ten residues.

18. The diagnostic system according to claim 17 where said HIV-1-related di-cys and di-leu polypeptides are present as an admixture.

19. The diagnostic system according to claim 17 wherein said HIV-2-related and HIV-1-related polypeptides are present as an admixture.

20. The diagnostic system according to claim 11 further including, in a separate package, a labeled specific binding agent for signaling the presence of a polypeptide-containing immunoreaction product.

21. The diagnostic system according to claim 11 wherein said polypeptide is affixed to a solid matrix.

-84-

22. The diagnostic system according to claim 11 further including an HIV-1-related polypeptide having an amino acid residue sequence represented by a formula selected from the group consisting of:

5 CSGKLIC,
IWGCSGKLICCTTAVP,
IWGCSGKLICTTAVPWNAS,
10 AVERYLKDQQLLGIWCSGKLI,
AVERYLKDQQLLGIWCSGKLICTTAVPWNAS,
LKDQQLLGIWCSGKLI,
LLGIWCSGKLIC,
QQLLGIWCSGKLICTTAVPWNAS,
15 IWGCSGKLICTTAVPWN,
CSGKLICTTAVPWNAS,
SGKLICTTAVPWNAS,
AVERYLKDQQLLGIWCSCKLIC,
GCSGKLICTTAVPWN,
20 LKDQQLLGIWCSGK, and
RILAVERYLKDQQLLGIWGCS.

23. A diagnostic system in kit form comprising:

a) a first solid support comprised of a solid matrix having operatively affixed thereto a HIV-2-related polypeptide having an amino acid residue sequence represented by a formula selected from the group consisting of:

30 AIEKYLEDDAQLNAWCAFRQVC,
AWCAFRQVCHTTVPWPNAS,
AIEKYLEDDAQLNAWGCAFRQVC,
AVEKYLKDQAQLNAWGCAFRQVC,
AIEKYLKDQAQLNSWGCAFRQVC,
SWGCAFRQVCHTSVPWVNDT,
35 AWGCAFRQVCHTTVPWPNAS,

-85-

AWGCAFRQVCHITVPWPNAS, and
CAFRQVC.

b) a second solid support comprised of a solid matrix having operatively affixed thereto, a
5 HIV-1-related di-cys polypeptide having an amino acid residue sequence represented by a formula selected from the group consisting of:

CSGKLIC,
IWGCSGKLICTTAVP,
10 IWGCSGKLICTTAVPWNAS,
AVERYLKDQQLLGIWCSGCKLI,
AVERYLKDQQLLGIWCSGCKLICTTAVPWNAS,
LLGIWCSGKLIC,
QQLLGIWCSGKLICTTAVPWNAS,
15 IWGCSGKLICTTAVPWN,
CSGKLICTTAVPWNAS,
AVERYLKDQQLLGIWCSGKLIC, and
GCSGKLICTTAVPWN; and

a HIV-1-related di-leu polypeptide having an amino
20 acid residue sequence represented by a formula selected from the group consisting of:

IWGCSGKLICTTAVPWNAS,
LKDQQLLGIWCSGLKI,
LKDQQLLGIWCSGK, and
25 RILAVERYLKDQQLLGIWGCS.

24. A diagnostic system in kit form comprising:

a) a first solid support comprised of a microtiter plate having operatively affixed thereto a
30 polypeptide having an amino acid residue sequence represented by the formula:

AIEKYLEDAQQLNAWGCAFRQVC and

b) a second solid support comprised of a microtiter plate having operatively affixed thereto,
35 in admixture, a first and a second HIV-1-related

-86-

polypeptides having amino acid residue sequences represent by the formula, respectively:

IWGCSGKLICTTAVPWNAS, and
AVERYLKDQQLLGIWGCSGCKLI.

5 25. A diagnostic system in kit form comprising a solid support comprised of a solid matrix having operatively affixed thereto, in admixture, first, second and third polypeptides having amino acid residue sequences represented by the formula,
10 respectively:

AIEKYLEDDAQLNAWGCAFRQVC,
IWGCSGKLICTTAVPWNAS, and
AVERYLKDQQLLGIWGCSGCKLI.

15

20

25

30

35

1/3

FIG. 1

STLV-III SEQUENCE:

5	10	15	20	25	30
AIEKYLEDAQQLNAWGCAFRQVCHTTVPWPNAS					

FIG. 2

HIV-1 SEQUENCE:

5	10	15	20	25	30
AVERYLKDQQLLGIWGCSGKLICTTAVPWNAS					

SUBSTITUTE SHEET

2 / 3

FIG. 3A

POLYPEPTIDE p80
(HIV-2-SPECIFIC)
ELISA





FIG. 3B


**POLYPEPTIDES III/IV
(V-I - SPECIFIC)**

ELISA



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US88/01140

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(4) C07K 7/06, 7/08, 7/10; C12Q 1/70; G01N 33/53, 33/532 U.S. CL. 530/324, 326, 327, 329, ; 435/5, 7, 805, 810; 436/506, 542, 808, 811		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	530/324, 326, 327, 329; 435/5, 7, 805, 810; 436/506, 542, 808, 811	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
Chemical Abstracts and Biological Abstracts online Computer Search.		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US, A, 4,629,783 (COSAND) 16 December 1986.	1-25
A,P	US, A, 4,735,896 (WANG et. al.). 05 April 1988.	1-25
A,P	CELL (Massachusetts, USA), volume 49 issued May 1987 (HIRSCH et al.) "The genome organization of STLV -3 is similar to that of the AIDS virus except for a truncated transmembrane protein", Pages 307-319.	1-25
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"Δ" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
14 JUNE 1988		14 JUL 1988
International Searching Authority		Signature of Authorized Officer
ISA/US		 CHRISTINA CHAN

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	<u>SCIENCE</u> (Washington, D.C. USA), volume 233, issued July 1986, (Clavel et al) "Isolation of a new human retrovirus from West African Patients with AIDS" pages 343-346.	1-25
X,P	<u>NATURE</u> (London, England), volume 329, issued 17 September 1987, (NORRBY et al), "Discrimination between antibodies to HIV and to related retroviruses using site-directed serology" pages 248-250. See pages 248,249,250	1-25